大鼠下颌骨成骨细胞对二甲双胍及普伐他汀的转运
|
摘要
糖尿病和骨质疏松症是影响人工种植牙修复的主要的系统性疾病。它们通过引起种植体周围的一系列的病理变化,进而影响骨组织的修复和重建,降低种植牙的成功率。二甲双胍不仅能够降低血糖,而且对种植体周围骨整合有促进作用;抗高脂血症药物普伐他汀,可以有效地治疗骨质疏松症,是目前发现的惟一能够既促进骨形成,又抑制骨吸收的药物。目前,在种植体周围局部给药成为研究的重点,特别是刘洪臣提出的人工种植体给药系统—即通过种植体与骨的接触,使药物转运到局部乃至全身,从而达到更好的治疗效果。为此,我们需要了解骨组织细胞对两种药物的转运能力。本实验通过观察两种药物在成骨细胞中的转运,探讨其可能的转运机制,为人工种植牙给药提供实验依据。
第一部分大鼠下颌骨成骨细胞跨膜转运
transwell模型的建立
目的:建立大鼠下颌骨成骨细胞跨膜转运transwell模型。
方法:分离培养大鼠下颌骨成骨细胞,并接种在transwell上室底部的聚碳酸脂膜上,光学显微镜观察其生长情况,扫描和透射电子显微镜观察细胞连接情况,跨膜电阻及荧光素钠通透实验检测细胞的屏障功能。
结果:成功培养并接种了大鼠下颌骨成骨细胞于聚碳酸脂膜上;光学显微镜观察,大鼠下颌骨成骨细胞(1×10~5/ml)接种2周后,细胞已完全汇合,连接紧密,并呈复层生长;扫描和透射电子显微镜显示,细胞间呈缝隙连接;细胞屏障功能检测,跨膜电阻随时间的增加而增加,第2周时达到最大(88.65±7.33)Ω/cm~2,并至少持续到接种后3周;荧光素钠通透性检测结果显示,孵育30min后只有0.17%的荧光素钠从transwell上室到达下室。
结论:应用transwell小室可以建立体外大鼠下颌骨成骨细胞复层生长的模型,并可用于药物细胞跨膜转运机制的研究。
第二部分大鼠下颌骨来源的成骨细胞对
二甲双胍的跨膜转运
目的:检测成骨细胞对二甲双胍的跨膜转运,研究其可能的转运机制,探讨人工种植牙给药的条件及可行性。
方法:高效液相色谱法测定转入及转出成骨细胞二甲双胍的量,同时考察时间、药物浓度、温度、pH值、有机阳离子转运蛋白(Octs)抑制剂西米替丁、二甲双胍类似物苯乙双胍以及P-糖蛋白(P-gp)抑制剂维拉帕米对二甲双胍转运的影响;免疫组化和RT-PCR检测Octs的表达,Western-blot检测二甲双胍对成骨细胞Oct1转运蛋白表达的影响。
结果:二甲双胍能够在成骨细胞上进行跨膜转运,且随着转运时间和药物浓度的增加而增加,并可达到饱和;一定范围内提高温度和pH值可以促进二甲双胍的转运;西米替丁和苯乙双胍对二甲双胍转运有明显抑制作用,而维拉帕米则对转运有明显的促进作用;Oct1广泛表达在成骨细胞的胞膜及胞浆中,而Oct2无表达;二甲双胍在不同浓度及不同给药时间均能够上调Oct1的表达,但各组间无明显差别。
结论:大鼠下颌骨来源成骨细胞能够对二甲双胍进行跨膜运输,且跨膜运输是通过Oct1为载体介导的协助扩散及P-gp为载体介导的主动转运的过程。
第三部分大鼠下颌骨来源的成骨细胞对
普伐他汀的跨膜转运
目的:检测成骨细胞对普伐他汀的跨膜转运,研究其可能的转运机制,探讨人工种植牙给药的条件及可行性。
方法:高效液相色谱法测定转入及转出成骨细胞普伐他汀的量,同时考察时间、药物浓度、温度、pH值、他汀类药物辛伐他汀和洛伐他汀以及P-糖蛋白(P-gp)抑制剂维拉帕米对普伐他汀转运的影响;免疫组化检测Oatpl的表达,Western-blot检测普伐他汀对成骨细胞Oatpl转运蛋白表达的影响。
结果:普伐他汀能够在成骨细胞上进行跨膜转运,且随着转运时间和药物浓度的增加而增加,并可达到饱和;一定范围内提高温度和pH值可以促进普伐他汀的转运;辛伐他汀和洛伐他汀对普伐他汀转运有明显抑制作用,而维拉帕米则对转运无明显作用;Oatp1广泛表达在成骨细胞的胞膜及胞浆中;普伐他汀在不同浓度及不同给药时间均能够上调Oatp1的表达,但各组间无明显差别。
结论:成骨细胞能够对普伐他汀进行跨膜运输,且跨膜运输是通过Oatp1为载体介导的协助扩散及非P-gp为载体介导的主动转运的过程。
Diabetes and osteoporosis are main systemic diseases that affect the dental implant treatment.They impact the restoration and reconstruction on bone tissue by inducing a series of pathological changes around the dental implant and decrease the success ratio of dental implant.Metformin,an anti-hyperglucose drug,can not only lower blood glucose,but also promote osseointegration around the implant;pravastatin,an anti-hyperlipidemic drug,can treat osteoporosis efficiently,and it is the only one that has the ability to promot the bone formation and inhibite the bone resorption.Therefore,topical administration around dental implant become the focus of the study in present.In particular,Liu Hong-chen proposed dental implant drug administration system—through the contact between implant and bone tissue,drugs can be transported to the local and the whole body so as to achieve the better therapeutic effects.So,we need to understand the capacity of transporting drugs by the bone tissue cells.In this study, we explored the possible transport mechanism through observing the transmembrane transport of metformin and pravastatin by osteoblasts from rat's mandible to provide the experimental basis for drug administration by dental implant.
PartⅠThe establishment of the transmembrane transport transwell model of rat mandible osteoblasts
Obsjective:To built the transmembrane transport transwell model of rat mandible osteoblasts.
Methods:Primary osteoblasts were isolated,cultured,identified and inoculated in the filter membrane of polycarbonate at the bottom of the upper well.Light microscope was utilized to observe the cells growth,scanning and transmission electron microscope was applied to observe the cell junction,membrane resistance and Fluorescein Sodium permeation experiment were detected the barrier function of osteoblasts.
Results:Osteoblasts were cultured and inoculated in the filter membrane of polycarbonate successfully;cells(1×10~5/ml)converged completely,connected closely and displayed ambi-layer generation 2 weeks after inoculation;tight junction between each cell was observed by scanning and transmission electron microscope;cells barrier function shown that TER of cells was increasing with time adding and reach the maximum(88.65±7.33)Ω/cm~2 which maintained till the 3rd week after inocubation;Fluorescein Sodium permeation experiment presented that after incubated for 30 minutes,only 0.17%of Fluorescein Sodium reached the inferior filter membrane.
Conclusions:The transwell can be used to set up the model of osteoblasts with growth of ambi-layer and investigate the mechanic of the transmembrane transport of drugs.
PartⅡThe transmembrane transport of metformin by osteoblasts from rat mandible
Objective:To detect the transmembrane transport of metformin by osteoblasts, investigate the possible mechanic of transport and explore the condition and feasibility of dental implant drug delivery.
Methods:HPLC(High Performance Liquid Chromatography)was utilized to detect the transmembrane transport of metformin by osteoblasts.The effect of time,drug concentration,temperature,pH,cimetidine(an inhibitor of organic cation transporter),and verapamil(an inhibito of P-protein)on the transport of metformin were studied.Octs(Organic cation transporters)expression were characterized by Immunocytochemistry and RT-PCR.Western blotting was ulilized to detect the effect ofmetformin on the expression of Oct1.
Results:Osteoblasts has the ability of transmembrane transport of metformin. The transport of metformin could be saturable with time and drug concentration adding;a certain range of temperature and pH can promote the transport of metformin;The transport of metformin was inhibited by cimetidine and phenformin,but promoted by verapamil;Oct1 but no Oct2 was expressed extensively in cell membrane and cytoplasm of osteoblasts;The protein level of Oct1 can be up-regulated by metformin with different drug concentrations and times,but no obvious differentces from each group.
Conclusions:Osteoblasts from rat mandible have the ability of transmembrane transport of metformin.,and the transport of metformin in osteoblasts was facilitated diffusion mediated by Oct1 and an active transportation mediated by P-gp which proves the possibility of the local drug delivery around dental implant in diabetes patients.
PartⅢThe transmembrane transport of pravastatin by osteoblasts from rat mandible
Objective:To detect the transmembrane transport of pravastatin by osteoblasts, investigate the possible mechanic of transport and explore the condition and feasibility of dental implant drug delivery.
Methods:HPLC(High Performance Liquid Chromatography)was utilized to detect the transmembrane transport of pravastatin by osteoblasts.The effect of time,drug concentration,temperature,pH,simvastain and lovastatin(the other stins)and verapamil on the transport of pravastatin were studied.Oatp1(Organic anion transporting polypeptide 1)expression were characterized by Immunocytochemistry.Western blotting was ulilized to detect the effect of pravastatin on the expression of Oatp1.
Results:Osteoblasts has the ability of transmembrane transport of metformin. The transport of metformin could be saturable with time and drug concentration adding;a certain range of temperature and pH can promote the transport of metformin;The transport of metformin was inhibited by simvastain and lovastatin, but not effected by verapamil;Oatp1 was expressed extensively in cell membrane and cytoplasm of osteoblasts;The protein level of Oatp1 can be up-regulated by pravastatin with different drug concentrations,but no obvious differentces from each group.
Conclusions:Osteoblasts from rat mandible have the ability of transmembrane transport of pravastatin,and the transport of pravastatin in osteoblasts was facilitated diffusion mediated by Oatp1 and an active transportation which proves the possibility of the loca1 drug delivery around dental implant in osteoporosis patients.
第一部分大鼠下颌骨成骨细胞跨膜转运
transwell模型的建立
目的:建立大鼠下颌骨成骨细胞跨膜转运transwell模型。
方法:分离培养大鼠下颌骨成骨细胞,并接种在transwell上室底部的聚碳酸脂膜上,光学显微镜观察其生长情况,扫描和透射电子显微镜观察细胞连接情况,跨膜电阻及荧光素钠通透实验检测细胞的屏障功能。
结果:成功培养并接种了大鼠下颌骨成骨细胞于聚碳酸脂膜上;光学显微镜观察,大鼠下颌骨成骨细胞(1×10~5/ml)接种2周后,细胞已完全汇合,连接紧密,并呈复层生长;扫描和透射电子显微镜显示,细胞间呈缝隙连接;细胞屏障功能检测,跨膜电阻随时间的增加而增加,第2周时达到最大(88.65±7.33)Ω/cm~2,并至少持续到接种后3周;荧光素钠通透性检测结果显示,孵育30min后只有0.17%的荧光素钠从transwell上室到达下室。
结论:应用transwell小室可以建立体外大鼠下颌骨成骨细胞复层生长的模型,并可用于药物细胞跨膜转运机制的研究。
第二部分大鼠下颌骨来源的成骨细胞对
二甲双胍的跨膜转运
目的:检测成骨细胞对二甲双胍的跨膜转运,研究其可能的转运机制,探讨人工种植牙给药的条件及可行性。
方法:高效液相色谱法测定转入及转出成骨细胞二甲双胍的量,同时考察时间、药物浓度、温度、pH值、有机阳离子转运蛋白(Octs)抑制剂西米替丁、二甲双胍类似物苯乙双胍以及P-糖蛋白(P-gp)抑制剂维拉帕米对二甲双胍转运的影响;免疫组化和RT-PCR检测Octs的表达,Western-blot检测二甲双胍对成骨细胞Oct1转运蛋白表达的影响。
结果:二甲双胍能够在成骨细胞上进行跨膜转运,且随着转运时间和药物浓度的增加而增加,并可达到饱和;一定范围内提高温度和pH值可以促进二甲双胍的转运;西米替丁和苯乙双胍对二甲双胍转运有明显抑制作用,而维拉帕米则对转运有明显的促进作用;Oct1广泛表达在成骨细胞的胞膜及胞浆中,而Oct2无表达;二甲双胍在不同浓度及不同给药时间均能够上调Oct1的表达,但各组间无明显差别。
结论:大鼠下颌骨来源成骨细胞能够对二甲双胍进行跨膜运输,且跨膜运输是通过Oct1为载体介导的协助扩散及P-gp为载体介导的主动转运的过程。
第三部分大鼠下颌骨来源的成骨细胞对
普伐他汀的跨膜转运
目的:检测成骨细胞对普伐他汀的跨膜转运,研究其可能的转运机制,探讨人工种植牙给药的条件及可行性。
方法:高效液相色谱法测定转入及转出成骨细胞普伐他汀的量,同时考察时间、药物浓度、温度、pH值、他汀类药物辛伐他汀和洛伐他汀以及P-糖蛋白(P-gp)抑制剂维拉帕米对普伐他汀转运的影响;免疫组化检测Oatpl的表达,Western-blot检测普伐他汀对成骨细胞Oatpl转运蛋白表达的影响。
结果:普伐他汀能够在成骨细胞上进行跨膜转运,且随着转运时间和药物浓度的增加而增加,并可达到饱和;一定范围内提高温度和pH值可以促进普伐他汀的转运;辛伐他汀和洛伐他汀对普伐他汀转运有明显抑制作用,而维拉帕米则对转运无明显作用;Oatp1广泛表达在成骨细胞的胞膜及胞浆中;普伐他汀在不同浓度及不同给药时间均能够上调Oatp1的表达,但各组间无明显差别。
结论:成骨细胞能够对普伐他汀进行跨膜运输,且跨膜运输是通过Oatp1为载体介导的协助扩散及非P-gp为载体介导的主动转运的过程。
Diabetes and osteoporosis are main systemic diseases that affect the dental implant treatment.They impact the restoration and reconstruction on bone tissue by inducing a series of pathological changes around the dental implant and decrease the success ratio of dental implant.Metformin,an anti-hyperglucose drug,can not only lower blood glucose,but also promote osseointegration around the implant;pravastatin,an anti-hyperlipidemic drug,can treat osteoporosis efficiently,and it is the only one that has the ability to promot the bone formation and inhibite the bone resorption.Therefore,topical administration around dental implant become the focus of the study in present.In particular,Liu Hong-chen proposed dental implant drug administration system—through the contact between implant and bone tissue,drugs can be transported to the local and the whole body so as to achieve the better therapeutic effects.So,we need to understand the capacity of transporting drugs by the bone tissue cells.In this study, we explored the possible transport mechanism through observing the transmembrane transport of metformin and pravastatin by osteoblasts from rat's mandible to provide the experimental basis for drug administration by dental implant.
PartⅠThe establishment of the transmembrane transport transwell model of rat mandible osteoblasts
Obsjective:To built the transmembrane transport transwell model of rat mandible osteoblasts.
Methods:Primary osteoblasts were isolated,cultured,identified and inoculated in the filter membrane of polycarbonate at the bottom of the upper well.Light microscope was utilized to observe the cells growth,scanning and transmission electron microscope was applied to observe the cell junction,membrane resistance and Fluorescein Sodium permeation experiment were detected the barrier function of osteoblasts.
Results:Osteoblasts were cultured and inoculated in the filter membrane of polycarbonate successfully;cells(1×10~5/ml)converged completely,connected closely and displayed ambi-layer generation 2 weeks after inoculation;tight junction between each cell was observed by scanning and transmission electron microscope;cells barrier function shown that TER of cells was increasing with time adding and reach the maximum(88.65±7.33)Ω/cm~2 which maintained till the 3rd week after inocubation;Fluorescein Sodium permeation experiment presented that after incubated for 30 minutes,only 0.17%of Fluorescein Sodium reached the inferior filter membrane.
Conclusions:The transwell can be used to set up the model of osteoblasts with growth of ambi-layer and investigate the mechanic of the transmembrane transport of drugs.
PartⅡThe transmembrane transport of metformin by osteoblasts from rat mandible
Objective:To detect the transmembrane transport of metformin by osteoblasts, investigate the possible mechanic of transport and explore the condition and feasibility of dental implant drug delivery.
Methods:HPLC(High Performance Liquid Chromatography)was utilized to detect the transmembrane transport of metformin by osteoblasts.The effect of time,drug concentration,temperature,pH,cimetidine(an inhibitor of organic cation transporter),and verapamil(an inhibito of P-protein)on the transport of metformin were studied.Octs(Organic cation transporters)expression were characterized by Immunocytochemistry and RT-PCR.Western blotting was ulilized to detect the effect ofmetformin on the expression of Oct1.
Results:Osteoblasts has the ability of transmembrane transport of metformin. The transport of metformin could be saturable with time and drug concentration adding;a certain range of temperature and pH can promote the transport of metformin;The transport of metformin was inhibited by cimetidine and phenformin,but promoted by verapamil;Oct1 but no Oct2 was expressed extensively in cell membrane and cytoplasm of osteoblasts;The protein level of Oct1 can be up-regulated by metformin with different drug concentrations and times,but no obvious differentces from each group.
Conclusions:Osteoblasts from rat mandible have the ability of transmembrane transport of metformin.,and the transport of metformin in osteoblasts was facilitated diffusion mediated by Oct1 and an active transportation mediated by P-gp which proves the possibility of the local drug delivery around dental implant in diabetes patients.
PartⅢThe transmembrane transport of pravastatin by osteoblasts from rat mandible
Objective:To detect the transmembrane transport of pravastatin by osteoblasts, investigate the possible mechanic of transport and explore the condition and feasibility of dental implant drug delivery.
Methods:HPLC(High Performance Liquid Chromatography)was utilized to detect the transmembrane transport of pravastatin by osteoblasts.The effect of time,drug concentration,temperature,pH,simvastain and lovastatin(the other stins)and verapamil on the transport of pravastatin were studied.Oatp1(Organic anion transporting polypeptide 1)expression were characterized by Immunocytochemistry.Western blotting was ulilized to detect the effect of pravastatin on the expression of Oatp1.
Results:Osteoblasts has the ability of transmembrane transport of metformin. The transport of metformin could be saturable with time and drug concentration adding;a certain range of temperature and pH can promote the transport of metformin;The transport of metformin was inhibited by simvastain and lovastatin, but not effected by verapamil;Oatp1 was expressed extensively in cell membrane and cytoplasm of osteoblasts;The protein level of Oatp1 can be up-regulated by pravastatin with different drug concentrations,but no obvious differentces from each group.
Conclusions:Osteoblasts from rat mandible have the ability of transmembrane transport of pravastatin,and the transport of pravastatin in osteoblasts was facilitated diffusion mediated by Oatp1 and an active transportation which proves the possibility of the loca1 drug delivery around dental implant in osteoporosis patients.
引文
[1]Hutton J E,Heath MR,Chai J Y,et al.Factors related to success and failure rates at 3-year follow-up in a multicenter study of overdetures supported by Branemark implants.Int J Oral Maxillofac Implant,1995,10:33.
[2]Adel R,Rockler B,et al.Branemark PI:A 15-year study of osseointegrated implants in the treatment of the edentulous jaw.Int J Oral Surg,1981,10:387.
[3]Adell R,Eriksson B,Lekholm U,et al.Long-term follow-up study of osseointegrated implants in the treament of total edentulous jaws.Int J Oral Maxillofac Implants,1990,10:347.
[4]Albrektsson T,Dahl E,Enbom L,et al.Ossointegrated oral implants;Swedish multicenter study of 8139 consecutively inserted Nobelpharma implants.J Periodontol,1988,59:287.
[5]张季平.临床内科学[M].天津:天津科学技术出版社,1999:2923-2955.
[6]Margonar mellitus and insulin therapy on biomechanical retention around dental implants:a study in rabbits[J].Implant Dent,2003,12(4):333-339.
[7]Siqueira JT,Cavalher-Machado SC,Arana-Chavez VE,et al.Bone formation around titanium implants in the rat tibia:role of insulin[J].Implant Dent,2003,12(3):242-251.
[8]郭月红,朱北兰.Ⅱ型糖尿病患者的牙周状况及对糖化血红蛋白(HbAlc) 的影响[J]．上海口腔医学,2004,13(2)：150-151．
[9]Peled M,Ardekian L,Tagger-Green N,et al.Dental implants in patients with type 2 diabetes mellitus:a clinical study[J].Implant Dent,2003,12(2):116-122.
[10]Abdulwassie H,Dhanrajani PJ.Diabetes mellitus and dental implants:a clinical study[J].Implant Dent,2002,1 l(1):83-86.
[11]Askary AS,Meffert RM,Griffin T.Why do dental implant fail? Part I[J].Implant Dent,1999,8(2):173-185.
[12]Fiorellini JP,Chen PK,Nevins M,et al.A retrospective study of dental implants in diabetic patients[J].Int J Periodont Res Dent,2000,20(4):366-373.
[13]01son JW,Shemoff AF,Tarlow JL,et al.Dental endosseous implant assessments in a type 2 diabetic population:a prospective study[J].Int J Oral Maxillofac Implant,2000,15(6):811-818.
[14]Balshi TJ,Wolfinger GJ.Dental implants in the diabetic patient:a retrospective study[J].Implant Dent,1999,8(4):355-359.
[15]Jeffcoat MK,Chesnut CH.3rd Systemic osteoporosis and oral bone loss:dvidence shows increaced risk factors.J Am Dent Assce,1993,124:49-56.
[16]Kirpichnikov D,McFar lane SI,Sowers JR.Metformin:an update[J].Ann Intern Med,2002,137(1):25-33
[17]Bailey CJ.Biguanides and NIDDM.Diabetes Care 1992;15:755-772.
[18]Harris MI,Hadden WC,Knowler WC,Bennett PH.Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S.population aged 20-74 yr.Diabetes 1987;36:523-534.
[19]Gall MA,Rossing P,Skott P,et al.Prevalence of micro-and macroalbuminuria,arterial hypertension,retinopathy and large vessel disease in European type 2 (non-insulin-dependent)diabetic patients.Diabetologia 1991;34:655-661.
[20]Nathan DM.Long-term complications of diabetes mellitus.N Engl J Med 1993;328:1676-1685.
[21]Garcia MJ,McNamara PM,Gordon T,Kannell WB.Morbidity and mortality in diabetics in the Framingham population:sixteen year follow-up study.Diabetes 1974;23:105-111.
[22]Panzram G.Mortality and survival in type 2(non-insulin-dependent)diabetes mellitus.Diabetologia 1987;30:123-131.Erratum,Diabetologia 1987;30:364.
[23]The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 1993;329:977-986.
[24]吕娇,刘洪臣,鄂玲玲等.盐酸二甲双胍对大鼠下颌骨成骨细胞增殖、分化及矿化功能的影响[J].中华老年口腔医学杂志,2008,6(1)48-50.
[25]Oxlund H,Dalstra M,Andreassen TT,et al.Statin given perorally to adult rats increases cancellous bone mass and compressive strength[J].Calcif Tissue Int,2001,69(5):299-304.
[26]Ohnaka K,Shimoda S,Nawata H,et al.Pitavastatin enhanced BMP-2 and osteocaclin expression by inhibition of Rho-associated kinase in human obsteoblasts[J].Biochem Biophys Res Commum,2001,287(2):337-342.
[27]Garretti R,Esparza J,Chen D,et al.Statins mediate their effects on osteoblasts by inhibition of HMG-COA reductase and ultimately BMP-2[J].J Bone Miner Res,2000,15(suppl):s225.
[28]Wonzeyj M,Rosen V.Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair[J].Clin Orthop,1998,346(1):26-37.
[29]Komori T,Yagi H,Nomura S,et al.Targeted disruption of Cbfal results in a complets lack of bone formation owing to maturational arrest of osteoblasts[J].Cell,1997,89(5):755-764.
[30]Mundlos S,Otto F,Mundlos C,et al.Mutation involving the transcription factor Cbfal cause cleidocranial dysplasia[J].Cell,1997,89(5):773-779.
[31]Scheidt-nave C,Bismar H,et al.Serum interleukin-6 is a major predictor of bone loss in women specific to the first decade past menopause[J].J Clin Endocrinol Metab,2001,86(5):2032-2042.
[32]刘洪臣.人工种植牙全身给药系统的设计[J].口腔颌面修复学杂志,2006,7(4):291-292
[1]刘洪臣.人工种植牙全身给药系统的设计[J].口腔颌面修复学杂志,2006,7(4):291-292
[2]Yee S.In vitro permeability across Caco-2 cells(colonic)can pre-dictin vivo(small intestinal)absorption in man-factor myth[J].PharmRes,1997,14(6):763-766.
[3]J.Jacobsen,B.van Deurs,M.Pedersen,et al.TR146 cells grown on filters as a model for human buccal epithelium:morphology,growth,barrier properties,andpermeability[J].Int.J.Pharm,1995,125:165-184
[4]司徒振强,吴军正.细胞培养[M].西安:世界图书出版公司,1996:111,188
[5]15.鄂玲玲,刘洪臣,吴霞,等.改良大鼠下颌骨成骨细胞原代培养与鉴定[J].中华老年口腔医学杂志,2007,5(4):226-229
[6]梁敏,廖二元.成人成骨细胞和MG-63细胞株孕激素受体的表达[J].中国骨质疏松杂志,2004,10(4):412-414
[7]Matschke C,Isele U,Fahr A,et al.Sustained-release injectables formed in situ and their potential use for veterinary products[J].J Control Rel,2002,85(1-3):1-15.
[8]Hatefi A,Amsden B.Biodegradable injectable in situ forming drug delivery systems[J].J Control Rel,2002,80:9-28.
[9]Kost J,Langer R.Responsive polymeric delivery systems[J].Adv Drug Deliv Rev,2001,46:125-148.
[10]Liberatore Rdel R Jr,Damiani D.Insulin pump therapy in type 1 diabetes mellitus.[J].J Pediatr,2006,82(4):249-254.
[11]Lebugle A,Rordrlgues A,Bonnevialle P,et al.Study of implantable calcium phosphate systems for the slowrelease of methorexate[J].Biomaterials,2002,23(16):3517-3522.
[12]KlemmKW.Antibiotic bead chains[J].Clin Orthop,1993,(295):63-76.
[13]Kelly J,David L,Tim A et al.Elution characteristics of tobramycin from polycaprolatone in a rabbit model[J].Clin Orthop,2001,(394):418-426.
[14]Dunn J P,Van Natta M,Foster G,et al.Complication of ganciclovir implant surgery in patients with cytomegalovirus retinitis trial[J].Retina.2004,24:41-45.
[15]Renard E,Costalat G,Chevassus H and et al.Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients[J].Diabetes Res and Clin Pract,2006,74 Suppl 2:173-177.
[16]Sykaras N,Iacopino AM,Triplett,RG.Effect of recombinant human bone morphogenetic protein-2 on the osseointegration of dental implants:a biomechanics study[J].Clin Oral Investig.2004,8(4):196-205.
[17]SykarasN,Woody RD;Lacopino,et al.Osseointegration of dental implants complexed with rhBMP-2:a comparative histomorphometric and radiographic evaluation[J].Int JoralMaxillofac Implants.2004,9(5):667-678.
[18]吴霞,刘洪臣,刘宇,等.大鼠下颌骨来源的成骨细胞对甲硝唑和替硝唑的转运[J].口腔颌面修复学杂志,2007,8(1):59-62.
[19]冷斌,刘洪臣,鄂玲玲,等.人牙龈成纤维细胞对甲硝唑的跨膜转运[J].中华老年口腔医学杂志,2007,5(2):100-103.
[20]刘宇,刘洪臣,吴霞,等.人牙周膜成纤维细胞对甲硝唑替硝唑的跨膜转运[J].口腔颌面修复学杂志,2007,8(2):90-93.
[21]Gan LS,Thankker DR.Applications of the Caco-2 model in the design and development of biochemical and physical barriers posed by the intestinal epithelium Adv Drug De livery Rev,1997,23(1-3):77-98.
[22]Yamashita S,Funrubayashi T,Kataoka M,et al Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur J Pharm Sci 2000,10(3):195-204
[23]Siok-Lam Lim and Lee-Yong Lim.Effects of citrus fruit juices on cyto toxicity and drug transport pathways of Caco-2 cell monolayers International Journal of Pharmaceutics,2006,307(1,3):42-50
[24]U Kristina Walle,Alema Galijatovicand,Thomas Walle.Transport of the flavonoid chrysin and its conjugated metab olites by the human intestinal cell line Caco-2 Biochemical Pharmacology,1999,58:431-438.
[25]Yutaka Takahashi,Hiromu Kondo,Tatsuo Yasuda,et al.Commen solubilizers to estimate the Caco-2 transport of poorly water soluble drugs International Journal of Phar maceutics,2002,246:85-94.
[26]H Lennernas,K Palm,U Fagerholm,P Artursson.Comparison between active and passive drug transport in human intestinal epithelial(Caco-2)cells in vitro and human jejunum in vivo International Journal of Pharmaceutics,1996,127:103 107
[27]关溯,赵立子,陈杰,等 Caco-2细胞模型的建立及意义 山东医药,2005,45(26):1-3.
[28]Dunn KC,Aotaki-Keen AE,Putkey FR,et al.ARPE-19,a human retinal pigment epithelial cell line with differentiated p roperties.Exp Eye Res,1996,62,155-169.
[29]A be T,Sugano E,Saigo Y,et al.Interleukin-1β and barrier function of retinal pigment epithelial cells (ARPE219):aberrant expression of junctional complex molecules.Invest Oph thalmol V is Sci,2003,44:4097-4104.
[1]张季平.临床内科学[M].天津:天津科学技术出版社,1999:2923-2955.
[2]Margonar mellitus and insulin therapy on biomechanical retention around dental implants:a study in rabbits[J].Implant Dent,2003,12(4):333-339.
[3]Siqueira JT,Cavalher-Machado SC,Arana-Chavez VE,et al.Bone formation around titanium implants in the rat tibia:role of insulin[J].Implant Dent,2003,12(3):242-251.
[4]郭月红,朱北兰.Ⅱ型糖尿病患者的牙周状况及对糖化血红蛋白(HbAlc)的影响[J].上海口腔医学,2004,13(2):150-151.
[5]Peled M,Ardekian L,Tagger-Green N,et al.Dental implants in patients with type 2 diabetes mellitus:a clinical study[J].Implant Dent,2003,12(2):116-122.
[6]Abdulwassie H,Dhanrajani PJ.Diabetes mellitus and dental implants:a clinical study[J].Implant Dent,2002,11(1):83-86.
[7]Askary AS,Meffert RM,Griffin T.Why do dental implant fail?Part Ⅰ[J].Implant Dent,1999,8(2):173-185.
[8]Fiorellini JP,Chen PK,Nevins M,et al.A retrospective study of dental implants in diabetic patients[J].Int J Periodont Res Dent,2000,20(4):366-373.
[9]Olson JW,Shemoff AF,Tarlow JL,et al.Dental endosseous implant assessments in a type 2 diabetic population:a prospective study[J].Int J Oral Maxillofac Implant,2000,15(6):811-818.
[10]Balshi TJ,Wolfinger GJ.Dental implants in the diabetic patient:a retrospective study[J].Implant Dent,1999,8(4):355-359.1.Kakuta S,Miyaoka K,Fujimori S,and et al.Proliferation and differentiation of bone marrow cells on titanium plates treated with a wire-type electrical discharge machine[J].J Oral Implantol,2000,26(3):156-162
[11]Gandhi A,Beam HA,O'Connor JP,et al.The effects of local insulin delivery on diabetic fracture healing[J].Bone.2005;37(4):482-90.
[12]Lobmann R,Zemlin C,Motzkau M,et al.Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing[J].J Diabetes Complications,2006;20(5):329-35.
[13]Qiu Z,Kwon AH,Kamiyama Y.Effects of plasma fibronectin on the healing of full-thickness skin wounds in streptozotocin-induced diabetic rats[J].J Surg Res,2007;138(1):64-70.
[14]Panzram G.Mortality and survival in type 2(non-insulin-dependent)diabetes mellitus.Diabetologia 1987;30:123-131.Erratum,Diabetologia 1987;30:364.
[15]The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 1993;329:977-986.
[16]吕娇,刘洪臣,鄂玲玲等.盐酸二甲双胍对大鼠下颌骨成骨细胞增殖、分化及矿化功能的影响[J].中华老年口腔医学杂志,2008,6(1)48-50.
[17]Fathi MH,Salehi M,Saatchi A,and et al.In vitro corrosion behavior of bioceramic,metallic,and bioceramic-metallic coated stainless steel dental implants[J].Dent Mater,2003,19(3):188-198
[18]Mellado-Valero A,Ferrer Garcia JC,Herrera Ballester A,and et al.Effects of diabetes on the osseointegration of dental implants[J].Med Oral Patol Oral Cir Bucal,2007,12(1):E38-43
[19]Kotsovilis S,Karoussis IK,Fourmousis I.A comprehensive and critical review of dental implant placement in diabetic animals and patients[J].Clin Oral Implants Res,2006,17(5):587-599
[20]Beikler T,Flemmig TF.Implants in the medically compromised patient[J].Crit Rev Oral Biol Med,2003;14(4):305-316
[21]van Steenberghe D,Jacobs R,Desnyder M,and et al.The relative impact of local and endogenous patient-related factors on implant failure up to the abutment stage [J].Clin Oral Implants Res,2002,13(6):617-622
[22]Farzad P,Andersson L,Nyberg J.Dental implant treatment in diabetic patients [J].Implant Dent,2002,11(3):262-267
[23]Jonker,JW.and Schinkel,AH.:Pharmacological and physiological functions of the polyspecific organic cation transporters:Oct 1,2,and 3 (SLC22A1-3).J.Pharmacol.Exp.Ther.,308(1):2-9 (2004).
[24]Jonker,J.W.,Wagenaar,E.,Mol,C.A.,Buitelaar,M.,Koepsell,H.,Smit,J.W.and Schinkel,A.H.:Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1[Slc22a1])gene.Mol.Cell Biol.,21(16):5471-5477 (2001).
[25]Jonker,J.W.,Wagenaar,E.,Van Eijl,S.and Schinkel,A.H.deficiency in the organic cation transporters 1 and 2(Octl/Oct2 [Slc22a1/Slc22a2])in mice abolishes renal secretion of organic cations.Mol.Cell Biol.,23(21):7902-7908(2003).
[26]Wang,D.S.,Jonker,J.W.,Kato,Y.,Kusuhara,H.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.J.Pharmacol.Exp.Ther.,302(2):510-515(2002).
[27]Wang,D.S.,Kusuhara,H.,Kato,Y.,Jonker,J.W.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.Mol.Pharmacol.,63(4):844-848 (2003).
[28]Zwart,R.,Verhaagh,S.,Buitelaar,M.,Popp-Snijders,C.and Barlow,D.P.:Impaired activity of the extraneuronal monoaminetransporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.Mol.Cell Biol.,21(13):4188-4196(2001).
[29]Saborowski,M.,Kullak-Ublick,G.A.and Eloranta,J.J.:The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha.J.Pharmacol.Exp.Ther.,317(2):778-785 (2006).
[30]Maeda,T.,Yotsumoto,T.,Oyabu,M.and Tamai,I.:Effect of glucocorticoid receptor ligand dexamethasone on the expression of organic cation transporter in rat liver.Drug Metab.Pharmacokinet.,23(1):67-72 (2008).
[31]Shu,Y.,Bello,C.L.,Mangravite,L.M.,Feng,B.and Giacomini,K.M.:Functional characteristics and steroid hormonemediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.J.Pharmacol.Exp.Ther.,299(1):392-398 (2001).
[32]Urakami,Y.,Nakamura,N.,Takahashi,K.,Okuda,M.,Saito,H.,Hashimoto,Y.and Inui,K.:Gender differences in expression of organic cation transporter Oct2 in rat kidney.FEBS Lett.,461:339-342 (1999).
[33]Asaka,J.,Terada,T.,Okuda,M.,Katsura,T.and Inui,K.:Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOctl and rOct3.Pharm.Res.,23(4):697-704 (2006).
[34]Kerb,R.,Brinkmann,U.,Chatskaia,N.,Gorbunov,D.,Gorboulev,V.,Mornhinweg,E.,Keil A,Eichelbaum,M.and Koepsell,H.:Identification of genetic variations of the human organic cation transporter hOctl and their functional consequences.Pharmacogenetics,12(8):591-595 (2002).
[35]Shu,Y.,Leabman,M.K.,Feng,B.,Mangravite,L.M.,Huang,C.C,Stryke,D.,Kawamoto,M.,Johns,S.J.,DeYoung,J.,Carlson,E.,Ferrin,T.E.,Herskowitz,I.and Giacomini,K.M.Evolutionary conservation predicts function of variants of the human organic cation transporter,Octl.Proc.Natl.Acad.Sci.USA.100(10):5902-5907 (2003).
[36]Sakata,T.,Anzai,N.,Shin,H.J.,Noshiro,R.,Hirata,T.,Yokoyama,H.,Kanai,Y.and Endou,H.:Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1)affecting transport functions.Biochem.Biophys.Res.Commun,313(3):789-793 (2004).
[37]Leabman,M.K.,Huang,C.C,Kawamoto,M,Johns,S.J.,Stryke,D., Ferrin,T.E.,DeYoung,J.,Taylor,T.,Clark,A.G.,Herskowitz,I.and Giacomini,K.M.:Polymorphisms in a human kidney xenobiotic transporter,Oct2,exhibit altered function.Pharmacogenetics,12(5):395-405 (2002).
[38]Lazar,A.,Grundemann,D.,Berkels,R.,Taubert,D.,Zimmermann,T.and Schomig,E.:Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).J.Hum.Genet.,48(5):226-30 (2003).
[39]Kimura,N.,Okuda,M.and Inui,K.:Metformin transport by renal basolateral organic cation transporter hOct2.Pharm.Res.,22(2):255-259 (2005).
[40]Shu,Y.,Sheardown,S.A.,Brown,C,Owen,R.P.,Zhang,S.,Castro,R.A.,Ianculescu,A.G.,Yue,L.,Lo,J.C,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1 (Octl)on metformin action.J Clin Invest.,117(5):1422-31 (2007).
[41]Shu,Y.,Brown,C,Castro,R.A.,Shi,R.J.,Lin,E.T.,Owen,R.P.,Sheardown,S.A.,Yue,L.,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1,Octl,on metformin pharmacokinetics.Clin.Pharmacol.Ther.,83(2):273-80 (2008).
[42]Azam,M.,Latek,R.R.and Daley,G.Q.:Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.Cell.,112(6):831-43 (2003).
[43]Zhou,G.,et al.Role of AMP-activated protein kinase in mechanism of metformin action.J.Clin.Invest.2001;108:1167-1174.
[44]Hardie,D.G.AMP-activated protein kinase as a drug target.Annu.Rev.Pharmacol.Toxicol.2007;47:185-210.
[45]Kim RB.Transporters and xenobiotic disposition[J].Toxicology,2002,181-182:291.
[46]Hoffmeyer S,Burk O,Richter OV,et al.Functional polymorphisms of the human multidrug resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].Proc Natl Acad Sci USA,2000,97 (7):3 473-3 478.
[47]Kim RB,Leake BF,Choo EF,et al.Identification of functionally variant MDRl alleles among European-Americans and African-Americans[J].Clin Pharmacol Ther,2001,70 (2):189-199.
[48]Schinkel AH,Smit JJM,Van Tellingen O,et al.Disruption of the mouse mdr 1 a P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs[J].Cell,1994,77(4):491-502.
[49]Song SH,Suzuki H,Kawai R,et al.Effect of PSC 833,a P-glycoprotein modulator,on the disposition of vincristine and digoxin in rats[J].Drug Metab Dispos,1999,27 (6):689-694.
[50]Greiner B,Eichelbaum M,Fritz P,et al.The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin[J].J Clin Invest,1999,104(2):147-153.
[51]Kim RB.Transporters and xenobiotic disposition [J].Toxicology,2002,181-182:291.
[1]Gilles JA,CamesDL,DallasMR,et al.Oral bone loss is increased in ovariectomized rats[J].J Endodon,1997,23:419-422.
[2]Jahangiri L,Kim A,Nishimura I.Effect of ovariectomy on the local residual ridge remodeling [J].J Prosthet Dent,1997,77:435-443.
[3]Southard TE,Soutard KA,Krizan KE,et al.Mandibular bone density and fractal dimension in rabbitswith induced osteoporosis[J].Oral Surg OralMed Oral Pathol Oral Radiol Endod,2000,89:244-249.
[4]Nishimura I,Hosokawa R,Kap Ian ML,et al.Animal model for evaluating the effect of systemic estrogen deficiency on residual ridge resorp tion[J].J Prosthet Dent,1995,73:304-310.
[5]Kribbs PJ.Comparison ofmandibular bone in normal and osteoporotic women[J].J Prosthet Dent,1990,63:218-222.
[6]Taguchi A,Tanimoto K,Suei Y,et al.Relationship between the mandibular and lumbar vertebral bone mineral density at different postmenopausal stages[J].Dentomaxillofac Radiol,1996,25:130-135.
[7]Streckfus CF,Johnson RB,Nick T,et al.Comparison of alveolar bone loss,alveolar bone density and secondmetacarpal bone density,salivary and gingival cervicular fluid interleukin26 concentrations in healthy p remenopausal and postmenopausal women on estrogen therapy[J].J Gerontol Biol SciMed Sci,1997,52 (6):343-351.
[8]Pluskiewicz W,Tarnawska B,Drozdzowska B.Mandibular bone mineral densitymeasured using dual 2energy X2ray absorp tiometry:relationship to hip bone mineral density and quantitative ultrasound at calcaneus and hand phalanges [J].The Br J Radiol,2000,73:288-292.
[9]Jonasson G,Kiliaridis S,Gumnarrson R.Cervical thickness of the mandibular alveolar p rocess and skeletal bonemineral density[J J.Acta Odontol Scan,1999,57:155-161.
[10]Hildebolt CF,Pilgram TK,DotsonM,et al.Estrogen and /or cocium plus calcium p lus vitamin D increase mandibular bone mass[J].J Periodontal,2004,75:811-816.
[11]Dao TT,Anderson JD,Zarb GA.Is osteoporosis a risk factor for osteointegration of dental imp lants? [J].Int J Oral Maxillofac Imp lants,1993,8: 137-144.
[12]Von Wowern N,Storm TL,Olgaard K.Bone mineral content by absorption merry of the mandible compared with that of the forearm and lumbar sp ine[J].Calcif Tissue Int,1988,42:157.
[13]Cho P,Schneider GB,Krizan K,et al.Examination of the bone implant interface in experimentally induced osteoporotic bone [J].Imp lant Dent,2004,13:79-87.
[14]Friberg B,Ekestubbe A,Mellstrom D,et al.Branemark imp lants and osteoporosis:a clinical exp loratory study [J].Clin Imp lant Dent Relat Res,2001,3:50-56.
[15]Stanford CM,Schneider GB.Functional behaviour of bone around dental imp lants[J].Gerodontology,2004,21:71-77.
[16]Oxlund H,Dalstra M,Andreassen TT,et al.Statin given perorally to adult rats increases cancellous bone mass and compressive strength [J].Calcif Tissue Int,2001,69 (5):299-304.
[17]Ohnaka K,Shimoda S,Nawata H,et al.Pitavastatin enhanced BMP-2 and osteocaclin expression by inhibition of Rho-associated kinase in human obsteoblasts[J].Biochem Biophys Res Commum,2001,287 (2):337-342.
[18]Garretti R,Esparza J,Chen D,et al.Statins mediate their effects on osteoblasts by inhibition of HMG-COA reductase and ultimately BMP-2 [J].J Bone Miner Res,2000,15 (suppl):s225.
[19]Wonzeyj M,Rosen V.Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair [J].Clin Orthop,1998,346 (1):26-37.
[20]Komori T,Yagi H,Nomura S,et al.Targeted disruption of Cbfal results in a complets lack of bone formation owing to maturational arrest of osteoblasts [J].Cell,1997,89 (5):755-764.
[21]Mundlos S,Otto F,Mundlos C,et al.Mutation involving the transcription factor Cbfal cause cleidocranial dysplasia[J].Cell,1997,89 (5):773-779.
[22]Scheidt-nave C,Bismar H,et al.Serum interleukin-6 is a major predictor of bone loss in women specific to the first decade past menopause [J].J Clin Endocrinol Metab,2001,86 (5):2032-2042.
[23]Hatanaka T.Clinical pharmacokinetics of pravastatin:mechanisms of pharmacokinetic events.Clin Pharmacokinet,2000,39(6):397-403
[24]Bonnie Hsiang,Yingjie Zhu,Zhaoqing Wang.A Novel Human Hepatic Organic Anion Transporting Polypeptide (Oatp2).J Bio Che,1999,274(52):37161-37168.
[25]Iwakiri T,Okumura M,Matsunaga N,Ichihara E,Shiotsuki S,Nagata M,Kumagai Y,Kai H,Arimori K.Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatpl protein level in rat hepatocytes.Eur J Pharmacol.2008,580(1-2):19-26.
[26]Geier A,Dietrich CG,Trauner M,Gartung C.Extrahepatic cholestasis downregulates Oatpl by TNF-alpha signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver.Liver Int.2007,27(8):1056-65.
[27]Hata S,Wang P,Eftychiou N,Ananthanarayanan M,Batta A,Salen G,Pang KS,Wolkoff AW.Substrate specificities of rat oatpl and ntcp:implications for hepatic organic anion uptake.Am J Physiol Gastrointest Liver Physiol.2003 Nov;285(5):G829-39.
[28]Lee TK,Koh AS,Cui Z,Pierce RH,Ballatori N.N-glycosylation controls functional activity of Oatpl,an organic anion transporter.Am J Physiol Gastrointest Liver Physiol.2003 Aug;285(2):G371-81.
[29]Gotoh Y,Kato Y,Stieger B,Meier PJ,Sugiyama Y.Gender difference in the Oatpl-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats.Am J Physiol Endocrinol Metab.2002 Jun;282(6):E1245-54.
[30]Meng LJ,Wang P,Wolkoff AW,Kim RB,Tirana RG,Hofmann AF,Pang KS.Transport of the sulfated,amidated bile acid,sulfolithocholyltaurine,into rat hepatocytes is mediated by Oatpl and Oatp2.Hepatology.2002 May;35(5):1031-40.
[31]Mittur A,Wolkoff AW,Kaplowitz N.The thiol sensitivity of glutathione transport in sidedness-sorted basolateral liver plasma membrane and in Oatpl-expressing HeLa cell membrane.Mol Pharmacol.2002 Feb;61(2):425-35.
[32]Cattori V,van Montfoort JE,Stieger B,Landmann L,Meijer DK,Winterhalter KH,Meier PJ,Hagenbuch B.Localization of organic anion transporting polypeptide 4 (Oatp4)in rat liver and comparison of its substrate specificity with Oatpl,Oatp2 and Oatp3.Pflugers Arch.2001 Nov;443(2):188-95.
[33]Rausch-Derra LC,Hartley DP,Meier PJ,Klaassen CD.Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters,Oatpl and Oatp2.Hepatology.2001,33(6):1469-78.
[34]Isern J,Hagenbuch B,Stieger B,Meier PJ,Meseguer A.Functional analysis and androgen-regulated expression of mouse organic anion transporting polypeptide 1 (Oatpl)in the kidney.Biochim Biophys Acta.2001,1518(l-2):73-8.
[35]Yamazaki M,Suzuki H,Sugiyama Y.Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics [J].Pharm Res,1996,13 (4):497-513.
[36]Hisang B,Zhu YJ,Wang ZQ,et al.A novel human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitors transporters [J].J B iol Chem,1999,274(52):37161-37168.
[37]Nakai D,Nakagomi R,Furuta Y,et al.Human liver specific organic anion transporter,LST21,mediates uptake of pravastatin by human hepatocytes [J].J Pharm acol Exp Ther,2001,297 (3):861-867.
[1]Grundemann,D.,Gorboulev,V.,Gambaryan,S.,Veyhl,M.and Koepsell,H.:Drug excretion mediated by a new prototype of polyspecific transporter.Nature,372(6506):549-552(1994).
[2]Gorboulev,V.,Ulzheimer,J.C.,Akhoundova,A.,Ulzheimer-Teuber,I.,Karbach,U.,Quester,S.,Baumann,C.,Lang,F.,Busch,A.E.and Koepsell,H.:Cloning and characterization of two human polyspecific organic cation transporters.DNA Cell Biol.,16(7):871-881(1997).
[3]Green,R.M.,Lo,K.,Sterritt,C.and Beier,D.R.:Cloning and functional expression of a mouse liver organic cation transporter.Hepatology,29(5):1556-1562(1999).
[4]Terashita,S.,Dresser,M.J.,Zhang,L.,Gray,A.T.,Yost,S.C.and Giacomini,K.M.:Molecular cloning and functional expression of a rabbit renal organic cation transporter.Biochim.Biophys.Acta.,1369(1):1-6(1998).
[5]Zhang,L.,Dresser,M.J.,Gray,A.T.,Yost,S.C.,Terashita,S.and Giacomini,K.M.:Cloning and functional expression of a human liver organic cation transporter.Mol.Pharmacol.,51(6):913-921(1997).
[6]Koepsell,H.,Lips,K.and Volk,C.:Polyspecific organic cation transporters:structure,function,physiological roles,and biopharmaceutical implications.Pharm.Res.,24(7):1227-51(2007).
[7]Zhang,X.,Evans,K.K.and Wright,S.H.:Molecular cloning of rabbit organic cation transporter rbOct2 and functional comparisons with rbOctl.Am.J.Physiol.Renal Physiol.,283(1):F124-F133 (2002).
[8]Arndt,P.,Volk,C,Gorboulev,V.,Budiman,T.,Popp,C,Ulzheimer-Teuber,I.,Akhoundova,A.,Koppatz,S.,Bamberg,E.,Nagel,G.and Koepsell,H.:Interaction of cations,anions,and weak base quinine with rat renal cation transporter rOct2 compared with rOctl.Am.J.Physiol.Renal Physiol.,281(3):F454-F468(2001).
[9]Kaewmokul,S.,Chatsudthipong,V.,Evans,K.K.,Dantzler,W.H.and Wright,S.H.:Functional mapping of rbOctl and rbOct2 activity in the S2 segment of rabbit proximal tubule.Am.J.Physiol.Renal Physiol.,285(6):F1149-F1159(2003).
[10]Koepsell,H.,Gorboulev,V.and Arndt,P.:Molecular pharmacology of organic cation transporters in kidney.J.Membr.Biol.,167(2):103-17 (1999).
[11]Jonker,J.W.and Schinkel,A.H.:Pharmacological and physiological functions of the polyspecific organic cation transporters:Oct 1,2,and 3 (SLC22A1-3).J.Pharmacol.Exp.Ther.,308(1):2-9 (2004).
[12]Jonker,J.W.,Wagenaar,E.,Mol,C.A.,Buitelaar,M.,Koepsell,H.,Smit,J.W.and Schinkel,A.H.:Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Octl[Slc22al])gene.Mol.Cell Biol.,21(16):5471-5477 (2001).
[13]Jonker,J.W.,Wagenaar,E.,Van Eijl,S.and Schinkel,A.H.deficiency in the organic cation transporters 1 and 2(Oct1/Oct2 [Slc22al/Slc22a2])in mice abolishes renal secretion of organic cations.Mol.Cell Biol.,23(21):7902-7908(2003).
[14]Wang,D.S.,Jonker,J.W.,Kato,Y.,Kusuhara,H.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.J.Pharmacol.Exp.Ther.,302(2):510-515 (2002).
[15]Wang,D.S.,Kusuhara,H.,Kato,Y.,Jonker,J.W.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.Mol.Pharmacol.,63(4):844-848 (2003).
[16]Zwart,R.,Verhaagh,S.,Buitelaar,M.,Popp-Snijders,C.and Barlow,D.P.:Impaired activity of the extraneuronal monoaminetransporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.Mol.Cell Biol.,21(13):4188-4196(2001).
[17]Cetinkaya,I.,Ciarimboli,G.,Yalcinkaya,G.,Mehrens,T.,Velic,A.,Hirsch,J.R.,Gorboulev,V.,Koepsell,H.and Schlatter,E.:Regulation of human organic cation transporter hOct2 by PKA,PI3K,and calmodulin-dependent kinases.Am.J.Physiol.Renal Physiol.,284(2):F293-F302 (2003).
[18]Ciarimboli,G.,Koepsell,H.,Iordanova,M.,Gorboulev,V.,Durner,B.,Lang,D.,Edemir,B.,Schroter,R.,Van Le,T.and Schlatter,E.:Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation.J.Am.Soc.Nephrol.,16(6):1562-1570 (2005).
[19]Denk,G.U.,Soroka,C.J.,Mennone,A.,Koepsell,H.,Beuers,U.and Boyer,J.L.:Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis.Hepatology,39(5):1382-1389 (2004).
[20]Biermann,J.,Lang,D.,Gorboulev,V.,Koepsell,H.,Sindic,A.,Schroter,R.,Zvirbliene,A.,Pavenstadt,H.,Schlatter,E.and Ciarimboli,G.:Characterization of regulatory mechanisms and states of human organic cation transporter 2.Am.J.Physiol.Cell Physiol.,290(6):C1521-C1531 (2006).
[21]Ciarimboli,G.and Schlatter,E.:Regulation of organic cation transport.Pflugers Arch.,449(5):423-441 (2005).
[22]Saborowski,M.,Kullak-Ublick,G.A.and Eloranta,J.J.:The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha.J. Pharmacol.Exp.Ther.,317(2):778-785 (2006).
[23]Nie,W.,Sweetser,S.,Rinella,M.and Green,R.M.:Transcriptional regulation of murine Slc22al (Octl)by peroxisome proliferator agonist receptor-alpha and-gamma.Am.J.Physiol.Gastrointest.Liver Physiol.,288(2):G207-G212 (2005).
[24]Maeda,T.,Oyabu,M.,Yotsumoto,T.,Higashi,R.,Nagata,K.,Yamazoe,Y.and Tamai,I.:Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Octl in rats.Drug Metab.Dispos.,35(9):1580-1586 (2007).
[25]Maeda,T.,Yotsumoto,T.,Oyabu,M.and Tamai,I.:Effect of glucocorticoid receptor ligand dexamethasone on the expression of organic cation transporter in rat liver.Drug Metab.Pharmacokinet.,23(1):67-72 (2008).
[26]Asaka,J.,Terada,T.,Ogasawara,K.,Katsura,T.and Inui,K.:Characterization of the Basal promoter element of human organic cation transporter 2 gene.J.Pharmacol.Exp.Ther.,321(2):684-689 (2007).
[27]Shu,Y.,Bello,C.L.,Mangravite,L.M.,Feng,B.and Giacomini,K.M.:Functional characteristics and steroid hormonemediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.J.Pharmacol.Exp.Ther.,299(1):392-398 (2001).
[28]Urakami,Y.,Nakamura,N.,Takahashi,K.,Okuda,M.,Saito,H.,Hashimoto,Y.and Inui,K.:Gender differences in expression of organic cation transporter Oct2 in rat kidney.FEBS Lett.,461:339-342 (1999).
[29]Urakami,Y.,Okuda,M.,Saito,H.and Inui,K.:Hormonal regulation of organic cation transporter Oct2 expression in rat kidney.FEBS Lett.,473:173-176(2000).
[30]Asaka,J.,Terada,T.,Okuda,M.,Katsura,T.and Inui,K.:Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOctl and rOct3.Pharm.Res.,23(4):697-704 (2006).
[31]Kerb,R.,Brinkmann,U.,Chatskaia,N.,Gorbunov,D.,Gorboulev,V.,Mornhinweg,E.,Keil A,Eichelbaum,M.and Koepsell,H.:Identification of genetic variations of the human organic cation transporter hOctl and their functional consequences.Pharmacogenetics,12(8):591-595 (2002).
[32]Shu,Y.,Leabman,M.K.,Feng,B.,Mangravite,L.M.,Huang,C.C,Stryke,D.,Kawamoto,M.,Johns,S.J.,DeYoung,J.,Carlson,E.,Ferrin,T.E.,Herskowitz,I.and Giacomini,K.M.:Evolutionary conservation predicts function of variants of the human organic cation transporter,Octl.Proc.Natl.Acad.Sci.USA.100(10):5902-5907(2003).
[33]Sakata,T.,Anzai,N.,Shin,H.J.,Noshiro,R.,Hirata,T.,Yokoyama,H.,Kanai,Y.and Endou,FL:Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1)affecting transport functions.Biochem.Biophys.Res.Commun,313(3):789-793 (2004).
[34]Takeuchi,A.,Motohashi,FL,Okuda,M.and Inui,K.:Decreased function of genetic variants,Pro283Leu and Arg287Gly,in human organic cation transporter hOctl.Drug Metab.Pharmacokinet.,18(6):409-412 (2003).
[35]Kang,H.L,Song,I.S.,Shin,H.L,Kim,W.Y.,Lee,C.H.,Shim,J.C,Zhou,H.FL,Lee,S.S.and Shin,J.G.:Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population.Drug Metab.Dispos.,35(4):667-675 (2007).
[36]Leabman,M.K.,Huang,C.C,Kawamoto,M.,Johns,S.L,Stryke,D.,Ferrin,T.E.,DeYoung,L,Taylor,T.,Clark,A.G.,Herskowitz,I.and Giacomini,K.M.:Polymorphisms in a human kidney xenobiotic transporter,Oct2,exhibit altered function.Pharmacogenetics,12(5):395-405 (2002).
[37]Fujita,T.,Urban,T.L,Leabman,M.K.,Fujita,K.and Giacomini,K.M.:Transport of drugs in the kidney by the human organic cation transporter,Oct2 and its genetic variants.J.Pharm.Sci.,95(1):25-36 (2006).
[38]Lazar,A.,Grundemann,D.,Berkels,R.,Taubert,D.,Zimmermann,T.and Schomig,E.:Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).J.Hum.Genet,48(5):226-30 (2003).
[39]Sirtori,C.R.,Franceschini,G.,Galli-Kienle,M.,Cighetti,G.,Galli,G.,Bondioli,A.and Conti,F.:Disposition of metformin (N,N-dimethylbiguanide)in man.Clin.Pharmacol.Ther.,24(6):683-693 (1978).
[40]Tucker,G.T.,Casey,C,Phillips,P.J.,Connor,H.,Ward,J.D.and Woods,H.F.:Metformin kinetics in healthy subjects and in patients with diabetes mellitus.Br.J.Clin.Pharmacol.,12(2):235-246 (1981).
[41]Bailey,C.J.:Biguanides and NIDDM.Diabetes Care.,15(6):755-772(1992).
[42]Somogyi,A.,Stockley,C,Keal,J.,Rolan,P.and Bochner,F.:Reduction of metformin renal tubular secretion by cimetidine in man.Br.J.Clin.Pharmacol.,23(5):545-551 (1987).
[43]Kimura,N.,Masuda,S.,Tanihara,Y.,Ueo,H.,Okuda,M.,Katsura,T.and Inui,K.:Metformin is a superior substrate for renal organic cation transporter Oct2 rather than hepatic Octl.Drug Metab.Pharmacokinet.,20(5):379-386(2005).
[44]Kimura,N.,Okuda,M.and Inui,K.:Metformin transport by renal basolateral organic cation transporter hOct2.Pharm.Res.,22(2):255-259 (2005).
[45]Shu,Y.,Sheardown,S.A.,Brown,C,Owen,R.P.,Zhang,S.,Castro,R.A.,Ianculescu,A.G.,Yue,L.,Lo,J.C,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1 (Octl)on metformin action.J Clin Invest.,117(5):1422-31 (2007).
[46]Shu,Y.,Brown,C,Castro,R.A.,Shi,R.J.,Lin,E.T.,Owen,R.P.,Sheardown,S.A.,Yue,L.,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1,Octl,on metformin pharmacokinetics.Clin.Pharmacol.Ther.,83(2):273-80 (2008).
[47]Grundemann,D.,Hahne,C,Berkels,R.and Schomig,E.:Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter(EMT) and organic cation transporter 2(Oct2).J.Pharmacol.Exp.Ther.,304(2):810-817(2003).
[48]Choi,M.K.,Jin,Q.R.,Jin,H.E.,Shim,C.K.,Cho,D.Y.,Shin,J.G.and Song,I.S.:Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin.Biopharm.Drug Dispos.,28(9):501-510(2007).
[49]刘洪臣.人工种植牙全身给药系统的设计[J].口腔颌面修复学杂志,2006,7(4):291-292
[2]Adel R,Rockler B,et al.Branemark PI:A 15-year study of osseointegrated implants in the treatment of the edentulous jaw.Int J Oral Surg,1981,10:387.
[3]Adell R,Eriksson B,Lekholm U,et al.Long-term follow-up study of osseointegrated implants in the treament of total edentulous jaws.Int J Oral Maxillofac Implants,1990,10:347.
[4]Albrektsson T,Dahl E,Enbom L,et al.Ossointegrated oral implants;Swedish multicenter study of 8139 consecutively inserted Nobelpharma implants.J Periodontol,1988,59:287.
[5]张季平.临床内科学[M].天津:天津科学技术出版社,1999:2923-2955.
[6]Margonar mellitus and insulin therapy on biomechanical retention around dental implants:a study in rabbits[J].Implant Dent,2003,12(4):333-339.
[7]Siqueira JT,Cavalher-Machado SC,Arana-Chavez VE,et al.Bone formation around titanium implants in the rat tibia:role of insulin[J].Implant Dent,2003,12(3):242-251.
[8]郭月红,朱北兰.Ⅱ型糖尿病患者的牙周状况及对糖化血红蛋白(HbAlc) 的影响[J]．上海口腔医学,2004,13(2)：150-151．
[9]Peled M,Ardekian L,Tagger-Green N,et al.Dental implants in patients with type 2 diabetes mellitus:a clinical study[J].Implant Dent,2003,12(2):116-122.
[10]Abdulwassie H,Dhanrajani PJ.Diabetes mellitus and dental implants:a clinical study[J].Implant Dent,2002,1 l(1):83-86.
[11]Askary AS,Meffert RM,Griffin T.Why do dental implant fail? Part I[J].Implant Dent,1999,8(2):173-185.
[12]Fiorellini JP,Chen PK,Nevins M,et al.A retrospective study of dental implants in diabetic patients[J].Int J Periodont Res Dent,2000,20(4):366-373.
[13]01son JW,Shemoff AF,Tarlow JL,et al.Dental endosseous implant assessments in a type 2 diabetic population:a prospective study[J].Int J Oral Maxillofac Implant,2000,15(6):811-818.
[14]Balshi TJ,Wolfinger GJ.Dental implants in the diabetic patient:a retrospective study[J].Implant Dent,1999,8(4):355-359.
[15]Jeffcoat MK,Chesnut CH.3rd Systemic osteoporosis and oral bone loss:dvidence shows increaced risk factors.J Am Dent Assce,1993,124:49-56.
[16]Kirpichnikov D,McFar lane SI,Sowers JR.Metformin:an update[J].Ann Intern Med,2002,137(1):25-33
[17]Bailey CJ.Biguanides and NIDDM.Diabetes Care 1992;15:755-772.
[18]Harris MI,Hadden WC,Knowler WC,Bennett PH.Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S.population aged 20-74 yr.Diabetes 1987;36:523-534.
[19]Gall MA,Rossing P,Skott P,et al.Prevalence of micro-and macroalbuminuria,arterial hypertension,retinopathy and large vessel disease in European type 2 (non-insulin-dependent)diabetic patients.Diabetologia 1991;34:655-661.
[20]Nathan DM.Long-term complications of diabetes mellitus.N Engl J Med 1993;328:1676-1685.
[21]Garcia MJ,McNamara PM,Gordon T,Kannell WB.Morbidity and mortality in diabetics in the Framingham population:sixteen year follow-up study.Diabetes 1974;23:105-111.
[22]Panzram G.Mortality and survival in type 2(non-insulin-dependent)diabetes mellitus.Diabetologia 1987;30:123-131.Erratum,Diabetologia 1987;30:364.
[23]The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 1993;329:977-986.
[24]吕娇,刘洪臣,鄂玲玲等.盐酸二甲双胍对大鼠下颌骨成骨细胞增殖、分化及矿化功能的影响[J].中华老年口腔医学杂志,2008,6(1)48-50.
[25]Oxlund H,Dalstra M,Andreassen TT,et al.Statin given perorally to adult rats increases cancellous bone mass and compressive strength[J].Calcif Tissue Int,2001,69(5):299-304.
[26]Ohnaka K,Shimoda S,Nawata H,et al.Pitavastatin enhanced BMP-2 and osteocaclin expression by inhibition of Rho-associated kinase in human obsteoblasts[J].Biochem Biophys Res Commum,2001,287(2):337-342.
[27]Garretti R,Esparza J,Chen D,et al.Statins mediate their effects on osteoblasts by inhibition of HMG-COA reductase and ultimately BMP-2[J].J Bone Miner Res,2000,15(suppl):s225.
[28]Wonzeyj M,Rosen V.Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair[J].Clin Orthop,1998,346(1):26-37.
[29]Komori T,Yagi H,Nomura S,et al.Targeted disruption of Cbfal results in a complets lack of bone formation owing to maturational arrest of osteoblasts[J].Cell,1997,89(5):755-764.
[30]Mundlos S,Otto F,Mundlos C,et al.Mutation involving the transcription factor Cbfal cause cleidocranial dysplasia[J].Cell,1997,89(5):773-779.
[31]Scheidt-nave C,Bismar H,et al.Serum interleukin-6 is a major predictor of bone loss in women specific to the first decade past menopause[J].J Clin Endocrinol Metab,2001,86(5):2032-2042.
[32]刘洪臣.人工种植牙全身给药系统的设计[J].口腔颌面修复学杂志,2006,7(4):291-292
[1]刘洪臣.人工种植牙全身给药系统的设计[J].口腔颌面修复学杂志,2006,7(4):291-292
[2]Yee S.In vitro permeability across Caco-2 cells(colonic)can pre-dictin vivo(small intestinal)absorption in man-factor myth[J].PharmRes,1997,14(6):763-766.
[3]J.Jacobsen,B.van Deurs,M.Pedersen,et al.TR146 cells grown on filters as a model for human buccal epithelium:morphology,growth,barrier properties,andpermeability[J].Int.J.Pharm,1995,125:165-184
[4]司徒振强,吴军正.细胞培养[M].西安:世界图书出版公司,1996:111,188
[5]15.鄂玲玲,刘洪臣,吴霞,等.改良大鼠下颌骨成骨细胞原代培养与鉴定[J].中华老年口腔医学杂志,2007,5(4):226-229
[6]梁敏,廖二元.成人成骨细胞和MG-63细胞株孕激素受体的表达[J].中国骨质疏松杂志,2004,10(4):412-414
[7]Matschke C,Isele U,Fahr A,et al.Sustained-release injectables formed in situ and their potential use for veterinary products[J].J Control Rel,2002,85(1-3):1-15.
[8]Hatefi A,Amsden B.Biodegradable injectable in situ forming drug delivery systems[J].J Control Rel,2002,80:9-28.
[9]Kost J,Langer R.Responsive polymeric delivery systems[J].Adv Drug Deliv Rev,2001,46:125-148.
[10]Liberatore Rdel R Jr,Damiani D.Insulin pump therapy in type 1 diabetes mellitus.[J].J Pediatr,2006,82(4):249-254.
[11]Lebugle A,Rordrlgues A,Bonnevialle P,et al.Study of implantable calcium phosphate systems for the slowrelease of methorexate[J].Biomaterials,2002,23(16):3517-3522.
[12]KlemmKW.Antibiotic bead chains[J].Clin Orthop,1993,(295):63-76.
[13]Kelly J,David L,Tim A et al.Elution characteristics of tobramycin from polycaprolatone in a rabbit model[J].Clin Orthop,2001,(394):418-426.
[14]Dunn J P,Van Natta M,Foster G,et al.Complication of ganciclovir implant surgery in patients with cytomegalovirus retinitis trial[J].Retina.2004,24:41-45.
[15]Renard E,Costalat G,Chevassus H and et al.Closed loop insulin delivery using implanted insulin pumps and sensors in type 1 diabetic patients[J].Diabetes Res and Clin Pract,2006,74 Suppl 2:173-177.
[16]Sykaras N,Iacopino AM,Triplett,RG.Effect of recombinant human bone morphogenetic protein-2 on the osseointegration of dental implants:a biomechanics study[J].Clin Oral Investig.2004,8(4):196-205.
[17]SykarasN,Woody RD;Lacopino,et al.Osseointegration of dental implants complexed with rhBMP-2:a comparative histomorphometric and radiographic evaluation[J].Int JoralMaxillofac Implants.2004,9(5):667-678.
[18]吴霞,刘洪臣,刘宇,等.大鼠下颌骨来源的成骨细胞对甲硝唑和替硝唑的转运[J].口腔颌面修复学杂志,2007,8(1):59-62.
[19]冷斌,刘洪臣,鄂玲玲,等.人牙龈成纤维细胞对甲硝唑的跨膜转运[J].中华老年口腔医学杂志,2007,5(2):100-103.
[20]刘宇,刘洪臣,吴霞,等.人牙周膜成纤维细胞对甲硝唑替硝唑的跨膜转运[J].口腔颌面修复学杂志,2007,8(2):90-93.
[21]Gan LS,Thankker DR.Applications of the Caco-2 model in the design and development of biochemical and physical barriers posed by the intestinal epithelium Adv Drug De livery Rev,1997,23(1-3):77-98.
[22]Yamashita S,Funrubayashi T,Kataoka M,et al Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells Eur J Pharm Sci 2000,10(3):195-204
[23]Siok-Lam Lim and Lee-Yong Lim.Effects of citrus fruit juices on cyto toxicity and drug transport pathways of Caco-2 cell monolayers International Journal of Pharmaceutics,2006,307(1,3):42-50
[24]U Kristina Walle,Alema Galijatovicand,Thomas Walle.Transport of the flavonoid chrysin and its conjugated metab olites by the human intestinal cell line Caco-2 Biochemical Pharmacology,1999,58:431-438.
[25]Yutaka Takahashi,Hiromu Kondo,Tatsuo Yasuda,et al.Commen solubilizers to estimate the Caco-2 transport of poorly water soluble drugs International Journal of Phar maceutics,2002,246:85-94.
[26]H Lennernas,K Palm,U Fagerholm,P Artursson.Comparison between active and passive drug transport in human intestinal epithelial(Caco-2)cells in vitro and human jejunum in vivo International Journal of Pharmaceutics,1996,127:103 107
[27]关溯,赵立子,陈杰,等 Caco-2细胞模型的建立及意义 山东医药,2005,45(26):1-3.
[28]Dunn KC,Aotaki-Keen AE,Putkey FR,et al.ARPE-19,a human retinal pigment epithelial cell line with differentiated p roperties.Exp Eye Res,1996,62,155-169.
[29]A be T,Sugano E,Saigo Y,et al.Interleukin-1β and barrier function of retinal pigment epithelial cells (ARPE219):aberrant expression of junctional complex molecules.Invest Oph thalmol V is Sci,2003,44:4097-4104.
[1]张季平.临床内科学[M].天津:天津科学技术出版社,1999:2923-2955.
[2]Margonar mellitus and insulin therapy on biomechanical retention around dental implants:a study in rabbits[J].Implant Dent,2003,12(4):333-339.
[3]Siqueira JT,Cavalher-Machado SC,Arana-Chavez VE,et al.Bone formation around titanium implants in the rat tibia:role of insulin[J].Implant Dent,2003,12(3):242-251.
[4]郭月红,朱北兰.Ⅱ型糖尿病患者的牙周状况及对糖化血红蛋白(HbAlc)的影响[J].上海口腔医学,2004,13(2):150-151.
[5]Peled M,Ardekian L,Tagger-Green N,et al.Dental implants in patients with type 2 diabetes mellitus:a clinical study[J].Implant Dent,2003,12(2):116-122.
[6]Abdulwassie H,Dhanrajani PJ.Diabetes mellitus and dental implants:a clinical study[J].Implant Dent,2002,11(1):83-86.
[7]Askary AS,Meffert RM,Griffin T.Why do dental implant fail?Part Ⅰ[J].Implant Dent,1999,8(2):173-185.
[8]Fiorellini JP,Chen PK,Nevins M,et al.A retrospective study of dental implants in diabetic patients[J].Int J Periodont Res Dent,2000,20(4):366-373.
[9]Olson JW,Shemoff AF,Tarlow JL,et al.Dental endosseous implant assessments in a type 2 diabetic population:a prospective study[J].Int J Oral Maxillofac Implant,2000,15(6):811-818.
[10]Balshi TJ,Wolfinger GJ.Dental implants in the diabetic patient:a retrospective study[J].Implant Dent,1999,8(4):355-359.1.Kakuta S,Miyaoka K,Fujimori S,and et al.Proliferation and differentiation of bone marrow cells on titanium plates treated with a wire-type electrical discharge machine[J].J Oral Implantol,2000,26(3):156-162
[11]Gandhi A,Beam HA,O'Connor JP,et al.The effects of local insulin delivery on diabetic fracture healing[J].Bone.2005;37(4):482-90.
[12]Lobmann R,Zemlin C,Motzkau M,et al.Expression of matrix metalloproteinases and growth factors in diabetic foot wounds treated with a protease absorbent dressing[J].J Diabetes Complications,2006;20(5):329-35.
[13]Qiu Z,Kwon AH,Kamiyama Y.Effects of plasma fibronectin on the healing of full-thickness skin wounds in streptozotocin-induced diabetic rats[J].J Surg Res,2007;138(1):64-70.
[14]Panzram G.Mortality and survival in type 2(non-insulin-dependent)diabetes mellitus.Diabetologia 1987;30:123-131.Erratum,Diabetologia 1987;30:364.
[15]The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.N Engl J Med 1993;329:977-986.
[16]吕娇,刘洪臣,鄂玲玲等.盐酸二甲双胍对大鼠下颌骨成骨细胞增殖、分化及矿化功能的影响[J].中华老年口腔医学杂志,2008,6(1)48-50.
[17]Fathi MH,Salehi M,Saatchi A,and et al.In vitro corrosion behavior of bioceramic,metallic,and bioceramic-metallic coated stainless steel dental implants[J].Dent Mater,2003,19(3):188-198
[18]Mellado-Valero A,Ferrer Garcia JC,Herrera Ballester A,and et al.Effects of diabetes on the osseointegration of dental implants[J].Med Oral Patol Oral Cir Bucal,2007,12(1):E38-43
[19]Kotsovilis S,Karoussis IK,Fourmousis I.A comprehensive and critical review of dental implant placement in diabetic animals and patients[J].Clin Oral Implants Res,2006,17(5):587-599
[20]Beikler T,Flemmig TF.Implants in the medically compromised patient[J].Crit Rev Oral Biol Med,2003;14(4):305-316
[21]van Steenberghe D,Jacobs R,Desnyder M,and et al.The relative impact of local and endogenous patient-related factors on implant failure up to the abutment stage [J].Clin Oral Implants Res,2002,13(6):617-622
[22]Farzad P,Andersson L,Nyberg J.Dental implant treatment in diabetic patients [J].Implant Dent,2002,11(3):262-267
[23]Jonker,JW.and Schinkel,AH.:Pharmacological and physiological functions of the polyspecific organic cation transporters:Oct 1,2,and 3 (SLC22A1-3).J.Pharmacol.Exp.Ther.,308(1):2-9 (2004).
[24]Jonker,J.W.,Wagenaar,E.,Mol,C.A.,Buitelaar,M.,Koepsell,H.,Smit,J.W.and Schinkel,A.H.:Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Oct1[Slc22a1])gene.Mol.Cell Biol.,21(16):5471-5477 (2001).
[25]Jonker,J.W.,Wagenaar,E.,Van Eijl,S.and Schinkel,A.H.deficiency in the organic cation transporters 1 and 2(Octl/Oct2 [Slc22a1/Slc22a2])in mice abolishes renal secretion of organic cations.Mol.Cell Biol.,23(21):7902-7908(2003).
[26]Wang,D.S.,Jonker,J.W.,Kato,Y.,Kusuhara,H.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.J.Pharmacol.Exp.Ther.,302(2):510-515(2002).
[27]Wang,D.S.,Kusuhara,H.,Kato,Y.,Jonker,J.W.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.Mol.Pharmacol.,63(4):844-848 (2003).
[28]Zwart,R.,Verhaagh,S.,Buitelaar,M.,Popp-Snijders,C.and Barlow,D.P.:Impaired activity of the extraneuronal monoaminetransporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.Mol.Cell Biol.,21(13):4188-4196(2001).
[29]Saborowski,M.,Kullak-Ublick,G.A.and Eloranta,J.J.:The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha.J.Pharmacol.Exp.Ther.,317(2):778-785 (2006).
[30]Maeda,T.,Yotsumoto,T.,Oyabu,M.and Tamai,I.:Effect of glucocorticoid receptor ligand dexamethasone on the expression of organic cation transporter in rat liver.Drug Metab.Pharmacokinet.,23(1):67-72 (2008).
[31]Shu,Y.,Bello,C.L.,Mangravite,L.M.,Feng,B.and Giacomini,K.M.:Functional characteristics and steroid hormonemediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.J.Pharmacol.Exp.Ther.,299(1):392-398 (2001).
[32]Urakami,Y.,Nakamura,N.,Takahashi,K.,Okuda,M.,Saito,H.,Hashimoto,Y.and Inui,K.:Gender differences in expression of organic cation transporter Oct2 in rat kidney.FEBS Lett.,461:339-342 (1999).
[33]Asaka,J.,Terada,T.,Okuda,M.,Katsura,T.and Inui,K.:Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOctl and rOct3.Pharm.Res.,23(4):697-704 (2006).
[34]Kerb,R.,Brinkmann,U.,Chatskaia,N.,Gorbunov,D.,Gorboulev,V.,Mornhinweg,E.,Keil A,Eichelbaum,M.and Koepsell,H.:Identification of genetic variations of the human organic cation transporter hOctl and their functional consequences.Pharmacogenetics,12(8):591-595 (2002).
[35]Shu,Y.,Leabman,M.K.,Feng,B.,Mangravite,L.M.,Huang,C.C,Stryke,D.,Kawamoto,M.,Johns,S.J.,DeYoung,J.,Carlson,E.,Ferrin,T.E.,Herskowitz,I.and Giacomini,K.M.Evolutionary conservation predicts function of variants of the human organic cation transporter,Octl.Proc.Natl.Acad.Sci.USA.100(10):5902-5907 (2003).
[36]Sakata,T.,Anzai,N.,Shin,H.J.,Noshiro,R.,Hirata,T.,Yokoyama,H.,Kanai,Y.and Endou,H.:Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1)affecting transport functions.Biochem.Biophys.Res.Commun,313(3):789-793 (2004).
[37]Leabman,M.K.,Huang,C.C,Kawamoto,M,Johns,S.J.,Stryke,D., Ferrin,T.E.,DeYoung,J.,Taylor,T.,Clark,A.G.,Herskowitz,I.and Giacomini,K.M.:Polymorphisms in a human kidney xenobiotic transporter,Oct2,exhibit altered function.Pharmacogenetics,12(5):395-405 (2002).
[38]Lazar,A.,Grundemann,D.,Berkels,R.,Taubert,D.,Zimmermann,T.and Schomig,E.:Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).J.Hum.Genet.,48(5):226-30 (2003).
[39]Kimura,N.,Okuda,M.and Inui,K.:Metformin transport by renal basolateral organic cation transporter hOct2.Pharm.Res.,22(2):255-259 (2005).
[40]Shu,Y.,Sheardown,S.A.,Brown,C,Owen,R.P.,Zhang,S.,Castro,R.A.,Ianculescu,A.G.,Yue,L.,Lo,J.C,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1 (Octl)on metformin action.J Clin Invest.,117(5):1422-31 (2007).
[41]Shu,Y.,Brown,C,Castro,R.A.,Shi,R.J.,Lin,E.T.,Owen,R.P.,Sheardown,S.A.,Yue,L.,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1,Octl,on metformin pharmacokinetics.Clin.Pharmacol.Ther.,83(2):273-80 (2008).
[42]Azam,M.,Latek,R.R.and Daley,G.Q.:Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL.Cell.,112(6):831-43 (2003).
[43]Zhou,G.,et al.Role of AMP-activated protein kinase in mechanism of metformin action.J.Clin.Invest.2001;108:1167-1174.
[44]Hardie,D.G.AMP-activated protein kinase as a drug target.Annu.Rev.Pharmacol.Toxicol.2007;47:185-210.
[45]Kim RB.Transporters and xenobiotic disposition[J].Toxicology,2002,181-182:291.
[46]Hoffmeyer S,Burk O,Richter OV,et al.Functional polymorphisms of the human multidrug resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J].Proc Natl Acad Sci USA,2000,97 (7):3 473-3 478.
[47]Kim RB,Leake BF,Choo EF,et al.Identification of functionally variant MDRl alleles among European-Americans and African-Americans[J].Clin Pharmacol Ther,2001,70 (2):189-199.
[48]Schinkel AH,Smit JJM,Van Tellingen O,et al.Disruption of the mouse mdr 1 a P-glycoprotein gene leads to a deficiency in the blood brain barrier and to increased sensitivity to drugs[J].Cell,1994,77(4):491-502.
[49]Song SH,Suzuki H,Kawai R,et al.Effect of PSC 833,a P-glycoprotein modulator,on the disposition of vincristine and digoxin in rats[J].Drug Metab Dispos,1999,27 (6):689-694.
[50]Greiner B,Eichelbaum M,Fritz P,et al.The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin[J].J Clin Invest,1999,104(2):147-153.
[51]Kim RB.Transporters and xenobiotic disposition [J].Toxicology,2002,181-182:291.
[1]Gilles JA,CamesDL,DallasMR,et al.Oral bone loss is increased in ovariectomized rats[J].J Endodon,1997,23:419-422.
[2]Jahangiri L,Kim A,Nishimura I.Effect of ovariectomy on the local residual ridge remodeling [J].J Prosthet Dent,1997,77:435-443.
[3]Southard TE,Soutard KA,Krizan KE,et al.Mandibular bone density and fractal dimension in rabbitswith induced osteoporosis[J].Oral Surg OralMed Oral Pathol Oral Radiol Endod,2000,89:244-249.
[4]Nishimura I,Hosokawa R,Kap Ian ML,et al.Animal model for evaluating the effect of systemic estrogen deficiency on residual ridge resorp tion[J].J Prosthet Dent,1995,73:304-310.
[5]Kribbs PJ.Comparison ofmandibular bone in normal and osteoporotic women[J].J Prosthet Dent,1990,63:218-222.
[6]Taguchi A,Tanimoto K,Suei Y,et al.Relationship between the mandibular and lumbar vertebral bone mineral density at different postmenopausal stages[J].Dentomaxillofac Radiol,1996,25:130-135.
[7]Streckfus CF,Johnson RB,Nick T,et al.Comparison of alveolar bone loss,alveolar bone density and secondmetacarpal bone density,salivary and gingival cervicular fluid interleukin26 concentrations in healthy p remenopausal and postmenopausal women on estrogen therapy[J].J Gerontol Biol SciMed Sci,1997,52 (6):343-351.
[8]Pluskiewicz W,Tarnawska B,Drozdzowska B.Mandibular bone mineral densitymeasured using dual 2energy X2ray absorp tiometry:relationship to hip bone mineral density and quantitative ultrasound at calcaneus and hand phalanges [J].The Br J Radiol,2000,73:288-292.
[9]Jonasson G,Kiliaridis S,Gumnarrson R.Cervical thickness of the mandibular alveolar p rocess and skeletal bonemineral density[J J.Acta Odontol Scan,1999,57:155-161.
[10]Hildebolt CF,Pilgram TK,DotsonM,et al.Estrogen and /or cocium plus calcium p lus vitamin D increase mandibular bone mass[J].J Periodontal,2004,75:811-816.
[11]Dao TT,Anderson JD,Zarb GA.Is osteoporosis a risk factor for osteointegration of dental imp lants? [J].Int J Oral Maxillofac Imp lants,1993,8: 137-144.
[12]Von Wowern N,Storm TL,Olgaard K.Bone mineral content by absorption merry of the mandible compared with that of the forearm and lumbar sp ine[J].Calcif Tissue Int,1988,42:157.
[13]Cho P,Schneider GB,Krizan K,et al.Examination of the bone implant interface in experimentally induced osteoporotic bone [J].Imp lant Dent,2004,13:79-87.
[14]Friberg B,Ekestubbe A,Mellstrom D,et al.Branemark imp lants and osteoporosis:a clinical exp loratory study [J].Clin Imp lant Dent Relat Res,2001,3:50-56.
[15]Stanford CM,Schneider GB.Functional behaviour of bone around dental imp lants[J].Gerodontology,2004,21:71-77.
[16]Oxlund H,Dalstra M,Andreassen TT,et al.Statin given perorally to adult rats increases cancellous bone mass and compressive strength [J].Calcif Tissue Int,2001,69 (5):299-304.
[17]Ohnaka K,Shimoda S,Nawata H,et al.Pitavastatin enhanced BMP-2 and osteocaclin expression by inhibition of Rho-associated kinase in human obsteoblasts[J].Biochem Biophys Res Commum,2001,287 (2):337-342.
[18]Garretti R,Esparza J,Chen D,et al.Statins mediate their effects on osteoblasts by inhibition of HMG-COA reductase and ultimately BMP-2 [J].J Bone Miner Res,2000,15 (suppl):s225.
[19]Wonzeyj M,Rosen V.Bone morphogenetic protein and bone morphogenetic protein gene family in bone formation and repair [J].Clin Orthop,1998,346 (1):26-37.
[20]Komori T,Yagi H,Nomura S,et al.Targeted disruption of Cbfal results in a complets lack of bone formation owing to maturational arrest of osteoblasts [J].Cell,1997,89 (5):755-764.
[21]Mundlos S,Otto F,Mundlos C,et al.Mutation involving the transcription factor Cbfal cause cleidocranial dysplasia[J].Cell,1997,89 (5):773-779.
[22]Scheidt-nave C,Bismar H,et al.Serum interleukin-6 is a major predictor of bone loss in women specific to the first decade past menopause [J].J Clin Endocrinol Metab,2001,86 (5):2032-2042.
[23]Hatanaka T.Clinical pharmacokinetics of pravastatin:mechanisms of pharmacokinetic events.Clin Pharmacokinet,2000,39(6):397-403
[24]Bonnie Hsiang,Yingjie Zhu,Zhaoqing Wang.A Novel Human Hepatic Organic Anion Transporting Polypeptide (Oatp2).J Bio Che,1999,274(52):37161-37168.
[25]Iwakiri T,Okumura M,Matsunaga N,Ichihara E,Shiotsuki S,Nagata M,Kumagai Y,Kai H,Arimori K.Hepatocyte growth factor increases uptake of estradiol 17beta-D-glucuronide and Oatpl protein level in rat hepatocytes.Eur J Pharmacol.2008,580(1-2):19-26.
[26]Geier A,Dietrich CG,Trauner M,Gartung C.Extrahepatic cholestasis downregulates Oatpl by TNF-alpha signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver.Liver Int.2007,27(8):1056-65.
[27]Hata S,Wang P,Eftychiou N,Ananthanarayanan M,Batta A,Salen G,Pang KS,Wolkoff AW.Substrate specificities of rat oatpl and ntcp:implications for hepatic organic anion uptake.Am J Physiol Gastrointest Liver Physiol.2003 Nov;285(5):G829-39.
[28]Lee TK,Koh AS,Cui Z,Pierce RH,Ballatori N.N-glycosylation controls functional activity of Oatpl,an organic anion transporter.Am J Physiol Gastrointest Liver Physiol.2003 Aug;285(2):G371-81.
[29]Gotoh Y,Kato Y,Stieger B,Meier PJ,Sugiyama Y.Gender difference in the Oatpl-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats.Am J Physiol Endocrinol Metab.2002 Jun;282(6):E1245-54.
[30]Meng LJ,Wang P,Wolkoff AW,Kim RB,Tirana RG,Hofmann AF,Pang KS.Transport of the sulfated,amidated bile acid,sulfolithocholyltaurine,into rat hepatocytes is mediated by Oatpl and Oatp2.Hepatology.2002 May;35(5):1031-40.
[31]Mittur A,Wolkoff AW,Kaplowitz N.The thiol sensitivity of glutathione transport in sidedness-sorted basolateral liver plasma membrane and in Oatpl-expressing HeLa cell membrane.Mol Pharmacol.2002 Feb;61(2):425-35.
[32]Cattori V,van Montfoort JE,Stieger B,Landmann L,Meijer DK,Winterhalter KH,Meier PJ,Hagenbuch B.Localization of organic anion transporting polypeptide 4 (Oatp4)in rat liver and comparison of its substrate specificity with Oatpl,Oatp2 and Oatp3.Pflugers Arch.2001 Nov;443(2):188-95.
[33]Rausch-Derra LC,Hartley DP,Meier PJ,Klaassen CD.Differential effects of microsomal enzyme-inducing chemicals on the hepatic expression of rat organic anion transporters,Oatpl and Oatp2.Hepatology.2001,33(6):1469-78.
[34]Isern J,Hagenbuch B,Stieger B,Meier PJ,Meseguer A.Functional analysis and androgen-regulated expression of mouse organic anion transporting polypeptide 1 (Oatpl)in the kidney.Biochim Biophys Acta.2001,1518(l-2):73-8.
[35]Yamazaki M,Suzuki H,Sugiyama Y.Recent advances in carrier-mediated hepatic uptake and biliary excretion of xenobiotics [J].Pharm Res,1996,13 (4):497-513.
[36]Hisang B,Zhu YJ,Wang ZQ,et al.A novel human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitors transporters [J].J B iol Chem,1999,274(52):37161-37168.
[37]Nakai D,Nakagomi R,Furuta Y,et al.Human liver specific organic anion transporter,LST21,mediates uptake of pravastatin by human hepatocytes [J].J Pharm acol Exp Ther,2001,297 (3):861-867.
[1]Grundemann,D.,Gorboulev,V.,Gambaryan,S.,Veyhl,M.and Koepsell,H.:Drug excretion mediated by a new prototype of polyspecific transporter.Nature,372(6506):549-552(1994).
[2]Gorboulev,V.,Ulzheimer,J.C.,Akhoundova,A.,Ulzheimer-Teuber,I.,Karbach,U.,Quester,S.,Baumann,C.,Lang,F.,Busch,A.E.and Koepsell,H.:Cloning and characterization of two human polyspecific organic cation transporters.DNA Cell Biol.,16(7):871-881(1997).
[3]Green,R.M.,Lo,K.,Sterritt,C.and Beier,D.R.:Cloning and functional expression of a mouse liver organic cation transporter.Hepatology,29(5):1556-1562(1999).
[4]Terashita,S.,Dresser,M.J.,Zhang,L.,Gray,A.T.,Yost,S.C.and Giacomini,K.M.:Molecular cloning and functional expression of a rabbit renal organic cation transporter.Biochim.Biophys.Acta.,1369(1):1-6(1998).
[5]Zhang,L.,Dresser,M.J.,Gray,A.T.,Yost,S.C.,Terashita,S.and Giacomini,K.M.:Cloning and functional expression of a human liver organic cation transporter.Mol.Pharmacol.,51(6):913-921(1997).
[6]Koepsell,H.,Lips,K.and Volk,C.:Polyspecific organic cation transporters:structure,function,physiological roles,and biopharmaceutical implications.Pharm.Res.,24(7):1227-51(2007).
[7]Zhang,X.,Evans,K.K.and Wright,S.H.:Molecular cloning of rabbit organic cation transporter rbOct2 and functional comparisons with rbOctl.Am.J.Physiol.Renal Physiol.,283(1):F124-F133 (2002).
[8]Arndt,P.,Volk,C,Gorboulev,V.,Budiman,T.,Popp,C,Ulzheimer-Teuber,I.,Akhoundova,A.,Koppatz,S.,Bamberg,E.,Nagel,G.and Koepsell,H.:Interaction of cations,anions,and weak base quinine with rat renal cation transporter rOct2 compared with rOctl.Am.J.Physiol.Renal Physiol.,281(3):F454-F468(2001).
[9]Kaewmokul,S.,Chatsudthipong,V.,Evans,K.K.,Dantzler,W.H.and Wright,S.H.:Functional mapping of rbOctl and rbOct2 activity in the S2 segment of rabbit proximal tubule.Am.J.Physiol.Renal Physiol.,285(6):F1149-F1159(2003).
[10]Koepsell,H.,Gorboulev,V.and Arndt,P.:Molecular pharmacology of organic cation transporters in kidney.J.Membr.Biol.,167(2):103-17 (1999).
[11]Jonker,J.W.and Schinkel,A.H.:Pharmacological and physiological functions of the polyspecific organic cation transporters:Oct 1,2,and 3 (SLC22A1-3).J.Pharmacol.Exp.Ther.,308(1):2-9 (2004).
[12]Jonker,J.W.,Wagenaar,E.,Mol,C.A.,Buitelaar,M.,Koepsell,H.,Smit,J.W.and Schinkel,A.H.:Reduced hepatic uptake and intestinal excretion of organic cations in mice with a targeted disruption of the organic cation transporter 1 (Octl[Slc22al])gene.Mol.Cell Biol.,21(16):5471-5477 (2001).
[13]Jonker,J.W.,Wagenaar,E.,Van Eijl,S.and Schinkel,A.H.deficiency in the organic cation transporters 1 and 2(Oct1/Oct2 [Slc22al/Slc22a2])in mice abolishes renal secretion of organic cations.Mol.Cell Biol.,23(21):7902-7908(2003).
[14]Wang,D.S.,Jonker,J.W.,Kato,Y.,Kusuhara,H.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.J.Pharmacol.Exp.Ther.,302(2):510-515 (2002).
[15]Wang,D.S.,Kusuhara,H.,Kato,Y.,Jonker,J.W.,Schinkel,A.H.and Sugiyama,Y.:Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.Mol.Pharmacol.,63(4):844-848 (2003).
[16]Zwart,R.,Verhaagh,S.,Buitelaar,M.,Popp-Snijders,C.and Barlow,D.P.:Impaired activity of the extraneuronal monoaminetransporter system known as uptake-2 in Orct3/Slc22a3-deficient mice.Mol.Cell Biol.,21(13):4188-4196(2001).
[17]Cetinkaya,I.,Ciarimboli,G.,Yalcinkaya,G.,Mehrens,T.,Velic,A.,Hirsch,J.R.,Gorboulev,V.,Koepsell,H.and Schlatter,E.:Regulation of human organic cation transporter hOct2 by PKA,PI3K,and calmodulin-dependent kinases.Am.J.Physiol.Renal Physiol.,284(2):F293-F302 (2003).
[18]Ciarimboli,G.,Koepsell,H.,Iordanova,M.,Gorboulev,V.,Durner,B.,Lang,D.,Edemir,B.,Schroter,R.,Van Le,T.and Schlatter,E.:Individual PKC-phosphorylation sites in organic cation transporter 1 determine substrate selectivity and transport regulation.J.Am.Soc.Nephrol.,16(6):1562-1570 (2005).
[19]Denk,G.U.,Soroka,C.J.,Mennone,A.,Koepsell,H.,Beuers,U.and Boyer,J.L.:Down-regulation of the organic cation transporter 1 of rat liver in obstructive cholestasis.Hepatology,39(5):1382-1389 (2004).
[20]Biermann,J.,Lang,D.,Gorboulev,V.,Koepsell,H.,Sindic,A.,Schroter,R.,Zvirbliene,A.,Pavenstadt,H.,Schlatter,E.and Ciarimboli,G.:Characterization of regulatory mechanisms and states of human organic cation transporter 2.Am.J.Physiol.Cell Physiol.,290(6):C1521-C1531 (2006).
[21]Ciarimboli,G.and Schlatter,E.:Regulation of organic cation transport.Pflugers Arch.,449(5):423-441 (2005).
[22]Saborowski,M.,Kullak-Ublick,G.A.and Eloranta,J.J.:The human organic cation transporter-1 gene is transactivated by hepatocyte nuclear factor-4alpha.J. Pharmacol.Exp.Ther.,317(2):778-785 (2006).
[23]Nie,W.,Sweetser,S.,Rinella,M.and Green,R.M.:Transcriptional regulation of murine Slc22al (Octl)by peroxisome proliferator agonist receptor-alpha and-gamma.Am.J.Physiol.Gastrointest.Liver Physiol.,288(2):G207-G212 (2005).
[24]Maeda,T.,Oyabu,M.,Yotsumoto,T.,Higashi,R.,Nagata,K.,Yamazoe,Y.and Tamai,I.:Effect of pregnane X receptor ligand on pharmacokinetics of substrates of organic cation transporter Octl in rats.Drug Metab.Dispos.,35(9):1580-1586 (2007).
[25]Maeda,T.,Yotsumoto,T.,Oyabu,M.and Tamai,I.:Effect of glucocorticoid receptor ligand dexamethasone on the expression of organic cation transporter in rat liver.Drug Metab.Pharmacokinet.,23(1):67-72 (2008).
[26]Asaka,J.,Terada,T.,Ogasawara,K.,Katsura,T.and Inui,K.:Characterization of the Basal promoter element of human organic cation transporter 2 gene.J.Pharmacol.Exp.Ther.,321(2):684-689 (2007).
[27]Shu,Y.,Bello,C.L.,Mangravite,L.M.,Feng,B.and Giacomini,K.M.:Functional characteristics and steroid hormonemediated regulation of an organic cation transporter in Madin-Darby canine kidney cells.J.Pharmacol.Exp.Ther.,299(1):392-398 (2001).
[28]Urakami,Y.,Nakamura,N.,Takahashi,K.,Okuda,M.,Saito,H.,Hashimoto,Y.and Inui,K.:Gender differences in expression of organic cation transporter Oct2 in rat kidney.FEBS Lett.,461:339-342 (1999).
[29]Urakami,Y.,Okuda,M.,Saito,H.and Inui,K.:Hormonal regulation of organic cation transporter Oct2 expression in rat kidney.FEBS Lett.,473:173-176(2000).
[30]Asaka,J.,Terada,T.,Okuda,M.,Katsura,T.and Inui,K.:Androgen receptor is responsible for rat organic cation transporter 2 gene regulation but not for rOctl and rOct3.Pharm.Res.,23(4):697-704 (2006).
[31]Kerb,R.,Brinkmann,U.,Chatskaia,N.,Gorbunov,D.,Gorboulev,V.,Mornhinweg,E.,Keil A,Eichelbaum,M.and Koepsell,H.:Identification of genetic variations of the human organic cation transporter hOctl and their functional consequences.Pharmacogenetics,12(8):591-595 (2002).
[32]Shu,Y.,Leabman,M.K.,Feng,B.,Mangravite,L.M.,Huang,C.C,Stryke,D.,Kawamoto,M.,Johns,S.J.,DeYoung,J.,Carlson,E.,Ferrin,T.E.,Herskowitz,I.and Giacomini,K.M.:Evolutionary conservation predicts function of variants of the human organic cation transporter,Octl.Proc.Natl.Acad.Sci.USA.100(10):5902-5907(2003).
[33]Sakata,T.,Anzai,N.,Shin,H.J.,Noshiro,R.,Hirata,T.,Yokoyama,H.,Kanai,Y.and Endou,FL:Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1)affecting transport functions.Biochem.Biophys.Res.Commun,313(3):789-793 (2004).
[34]Takeuchi,A.,Motohashi,FL,Okuda,M.and Inui,K.:Decreased function of genetic variants,Pro283Leu and Arg287Gly,in human organic cation transporter hOctl.Drug Metab.Pharmacokinet.,18(6):409-412 (2003).
[35]Kang,H.L,Song,I.S.,Shin,H.L,Kim,W.Y.,Lee,C.H.,Shim,J.C,Zhou,H.FL,Lee,S.S.and Shin,J.G.:Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population.Drug Metab.Dispos.,35(4):667-675 (2007).
[36]Leabman,M.K.,Huang,C.C,Kawamoto,M.,Johns,S.L,Stryke,D.,Ferrin,T.E.,DeYoung,L,Taylor,T.,Clark,A.G.,Herskowitz,I.and Giacomini,K.M.:Polymorphisms in a human kidney xenobiotic transporter,Oct2,exhibit altered function.Pharmacogenetics,12(5):395-405 (2002).
[37]Fujita,T.,Urban,T.L,Leabman,M.K.,Fujita,K.and Giacomini,K.M.:Transport of drugs in the kidney by the human organic cation transporter,Oct2 and its genetic variants.J.Pharm.Sci.,95(1):25-36 (2006).
[38]Lazar,A.,Grundemann,D.,Berkels,R.,Taubert,D.,Zimmermann,T.and Schomig,E.:Genetic variability of the extraneuronal monoamine transporter EMT (SLC22A3).J.Hum.Genet,48(5):226-30 (2003).
[39]Sirtori,C.R.,Franceschini,G.,Galli-Kienle,M.,Cighetti,G.,Galli,G.,Bondioli,A.and Conti,F.:Disposition of metformin (N,N-dimethylbiguanide)in man.Clin.Pharmacol.Ther.,24(6):683-693 (1978).
[40]Tucker,G.T.,Casey,C,Phillips,P.J.,Connor,H.,Ward,J.D.and Woods,H.F.:Metformin kinetics in healthy subjects and in patients with diabetes mellitus.Br.J.Clin.Pharmacol.,12(2):235-246 (1981).
[41]Bailey,C.J.:Biguanides and NIDDM.Diabetes Care.,15(6):755-772(1992).
[42]Somogyi,A.,Stockley,C,Keal,J.,Rolan,P.and Bochner,F.:Reduction of metformin renal tubular secretion by cimetidine in man.Br.J.Clin.Pharmacol.,23(5):545-551 (1987).
[43]Kimura,N.,Masuda,S.,Tanihara,Y.,Ueo,H.,Okuda,M.,Katsura,T.and Inui,K.:Metformin is a superior substrate for renal organic cation transporter Oct2 rather than hepatic Octl.Drug Metab.Pharmacokinet.,20(5):379-386(2005).
[44]Kimura,N.,Okuda,M.and Inui,K.:Metformin transport by renal basolateral organic cation transporter hOct2.Pharm.Res.,22(2):255-259 (2005).
[45]Shu,Y.,Sheardown,S.A.,Brown,C,Owen,R.P.,Zhang,S.,Castro,R.A.,Ianculescu,A.G.,Yue,L.,Lo,J.C,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1 (Octl)on metformin action.J Clin Invest.,117(5):1422-31 (2007).
[46]Shu,Y.,Brown,C,Castro,R.A.,Shi,R.J.,Lin,E.T.,Owen,R.P.,Sheardown,S.A.,Yue,L.,Burchard,E.G.,Brett,C.M.and Giacomini,K.M.:Effect of genetic variation in the organic cation transporter 1,Octl,on metformin pharmacokinetics.Clin.Pharmacol.Ther.,83(2):273-80 (2008).
[47]Grundemann,D.,Hahne,C,Berkels,R.and Schomig,E.:Agmatine is efficiently transported by non-neuronal monoamine transporters extraneuronal monoamine transporter(EMT) and organic cation transporter 2(Oct2).J.Pharmacol.Exp.Ther.,304(2):810-817(2003).
[48]Choi,M.K.,Jin,Q.R.,Jin,H.E.,Shim,C.K.,Cho,D.Y.,Shin,J.G.and Song,I.S.:Effects of tetraalkylammonium compounds with different affinities for organic cation transporters on the pharmacokinetics of metformin.Biopharm.Drug Dispos.,28(9):501-510(2007).
[49]刘洪臣.人工种植牙全身给药系统的设计[J].口腔颌面修复学杂志,2006,7(4):291-292